<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">91766</article-id><article-id pub-id-type="doi">10.7554/eLife.91766</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.91766.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Netrin signaling mediates survival of dormant epithelial ovarian cancer cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Perampalam</surname><given-names>Pirunthan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>MacDonald</surname><given-names>James I</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zakirova</surname><given-names>Komila</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Passos</surname><given-names>Daniel T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3530-2821</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wasif</surname><given-names>Sumaiyah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ramos-Valdes</surname><given-names>Yudith</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hervieu</surname><given-names>Maeva</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mehlen</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Rottapel</surname><given-names>Rob</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gibert</surname><given-names>Benjamin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5295-3124</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Correa</surname><given-names>Rohann JM</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shepherd</surname><given-names>Trevor G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Dick</surname><given-names>Frederick A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0047-9985</contrib-id><email>fdick@uwo.ca</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>London Regional Cancer Program, London Health Sciences Centre Research Institute</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02grkyz14</institution-id><institution>Department of Biochemistry, University of Western Ontario</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02grkyz14</institution-id><institution>Department of Pathology and Laboratory Medicine, University of Western Ontario</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff><aff id="aff4"><label>4</label><institution>The Mary and John Knight Translational Ovarian Cancer Research Unit, London Regional Cancer Program</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cmnjq37</institution-id><institution>Apoptosis, Cancer and Development Laboratory - Equipe labellisée ‘La Ligue’, LabEx DEVweCAN, Institut Convergence PLAsCAN, Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon1, Centre Léon Bérard</institution></institution-wrap><addr-line><named-content content-type="city">Lyon</named-content></addr-line><country>France</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00ws9ra62</institution-id><institution>Netris Pharma</institution></institution-wrap><addr-line><named-content content-type="city">Lyon</named-content></addr-line><country>France</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042xt5161</institution-id><institution>Princess Margaret Cancer Centre, University Health Network</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>Department of Medical Biophysics, University of Toronto, 1 King’s College Circle</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02grkyz14</institution-id><institution>Department of Oncology, Western University</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02grkyz14</institution-id><institution>Department of Obstetrics and Gynecology, Western University</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02grkyz14</institution-id><institution>Department of Anatomy and Cell Biology, Western University</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/038pa9k74</institution-id><institution>Children's Health Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Topisirovic</surname><given-names>Ivan</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056jjra10</institution-id><institution>Jewish General Hospital</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>18</day><month>07</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP91766</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-08-15"><day>15</day><month>08</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-08-31"><day>31</day><month>08</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.08.29.555435"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-30"><day>30</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.91766.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-06-25"><day>25</day><month>06</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.91766.2"/></event></pub-history><permissions><copyright-statement>© 2023, Perampalam et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Perampalam et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-91766-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-91766-figures-v1.pdf"/><abstract><p>Dormancy in cancer is a clinical state in which residual disease remains undetectable for a prolonged duration. At a cellular level, rare cancer cells cease proliferation and survive chemotherapy and disseminate disease. We created a suspension culture model of high-grade serous ovarian cancer (HGSOC) dormancy and devised a novel CRISPR screening approach to identify survival genes in this context. In combination with RNA-seq, we discovered the Netrin signaling pathway as critical to dormant HGSOC cell survival. We demonstrate that Netrin-1, –3, and its receptors are essential for low level ERK activation to promote survival, and that Netrin activation of ERK is unable to induce proliferation. Deletion of all UNC5 family receptors blocks Netrin signaling in HGSOC cells and compromises viability during the dormancy step of dissemination in xenograft assays. Furthermore, we demonstrate that Netrin-1 and –3 overexpression in HGSOC correlates with poor outcome. Specifically, our experiments reveal that Netrin overexpression elevates cell survival in dormant culture conditions and contributes to greater spread of disease in a xenograft model of abdominal dissemination. This study highlights Netrin signaling as a key mediator HGSOC cancer cell dormancy and metastasis.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>High-grade serous ovarian cancer (or HGSOC for short) is the fifth leading cause of cancer-related deaths in women. It is generally diagnosed at an advanced stage of disease when the cancer has already spread to other parts of the body. Surgical removal of tumors and subsequent treatment with chemotherapy often reduces the signs and symptoms of the disease for a time but some cancer cells tend to survive so that patients eventually relapse.</p><p>The HGSOC cells typically spread from the ovaries by moving through the liquid surrounding organs in the abdomen. The cells clump together and enter an inactive state known as dormancy that allows them to survive chemotherapy and low-nutrient conditions. Understanding how to develop new drug therapies that target dormant cancer cells is thought to be an important step in prolonging the life of HGSOC patients.</p><p>Cancer cells are hardwired to multiply and grow, so Perampalam et al. reasoned that becoming dormant poses challenges for HGSOC cells, which may create unique vulnerabilities not shared by proliferating cancer cells. To find out more, the researchers used HGSOC cells that had been isolated from patients and grown in the laboratory. The team used a gene editing technique to screen HGSOC cells for genes required by the cells to survive when they are dormant.</p><p>The experiments found that genes involved in a cell signaling pathway, known as Netrin signaling, were critical for the cells to survive. Previous studies have shown that Netrin signaling helps the nervous system form in embryos and inhibits a program of controlled cell death in some cancers. Perampalam et al. discovered that Netrins were present in the environment immediately surrounding dormant HGSOC cells. Human HGSOC patients with higher levels of Netrin gene expression had poorer prognoses than patients with lower levels of Netrin gene expression. Further experiments demonstrated that Netrins help dormant HGSOC cells to spread around the body.</p><p>These findings suggest that Netrin signalling may provide useful targets for future drug therapies against dormant cells in some ovarian cancers. This could include repurposing drugs already in development or creating new inhibitors of this pathway.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Netrin</kwd><kwd>high grade serous ovarian cancer</kwd><kwd>Dyrk1a</kwd><kwd>dormancy</kwd><kwd>quiescence</kwd><kwd>spheroids</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009326</institution-id><institution>Cancer Research Society</institution></institution-wrap></funding-source><award-id>23150</award-id><principal-award-recipient><name><surname>Dick</surname><given-names>Frederick A</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009326</institution-id><institution>Cancer Research Society</institution></institution-wrap></funding-source><award-id>25021</award-id><principal-award-recipient><name><surname>Dick</surname><given-names>Frederick A</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004203</institution-id><institution>Ontario Institute for Cancer Research</institution></institution-wrap></funding-source><award-id>P.CTIP.966</award-id><principal-award-recipient><name><surname>Dick</surname><given-names>Frederick A</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>PJT173391</award-id><principal-award-recipient><name><surname>Dick</surname><given-names>Frederick A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Extending the period of remission for cancer patients requires new knowledge of dormant, residual disease and Netrin signaling contributes to the survival of dormant cells in ovarian cancer.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Relapse from initially effective cancer treatment represents one of the greatest barriers to improving outcomes (<xref ref-type="bibr" rid="bib26">Giancotti, 2013</xref>). Dormant or minimal residual disease that is not clinically detectable is a common source of relapse, particularly in a metastatic setting (<xref ref-type="bibr" rid="bib43">Massagué and Ganesh, 2021</xref>). This has motivated the search for, and study of, disseminated cancer cells. Cellular dormancy has been characterized in cancer cells derived from a variety of primary disease sites including breast, prostate, melanoma, and others (<xref ref-type="bibr" rid="bib61">Sosa et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Phan and Croucher, 2020</xref>). Disseminated cells often occupy specific cellular niches in perivascular space or in bone marrow (<xref ref-type="bibr" rid="bib27">Goddard et al., 2018</xref>). They adopt catabolic metabolism (<xref ref-type="bibr" rid="bib43">Massagué and Ganesh, 2021</xref>), and withdraw from the cell cycle (<xref ref-type="bibr" rid="bib54">Phan and Croucher, 2020</xref>). Stem like phenotypes and epithelial to mesenchymal transition also characterize the biology of these cells as they survive dissemination and lay quiescent in distant tissues (<xref ref-type="bibr" rid="bib26">Giancotti, 2013</xref>; <xref ref-type="bibr" rid="bib61">Sosa et al., 2014</xref>; <xref ref-type="bibr" rid="bib27">Goddard et al., 2018</xref>). Across a variety of disease sites this dormant state is characterized by diminished Ras-MAPK signaling and elevated p38 activity (<xref ref-type="bibr" rid="bib61">Sosa et al., 2014</xref>; <xref ref-type="bibr" rid="bib64">Yeh and Ramaswamy, 2015</xref>). To develop treatments specifically tailored for dormant cells, a systematic search for vulnerabilities unique to dormancy is needed. To this end, high-grade serous ovarian cancer (HGSOC) disseminates in ascites as growth arrested cellular aggregates (<xref ref-type="bibr" rid="bib14">Correa et al., 2012</xref>). This has been modeled in culture (<xref ref-type="bibr" rid="bib37">Lengyel et al., 2014</xref>), and studies confirm active induction of cell cycle arrest mechanisms (<xref ref-type="bibr" rid="bib30">Hu et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">MacDonald et al., 2017</xref>), induction of autophagy (<xref ref-type="bibr" rid="bib15">Correa et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Correa et al., 2015</xref>), and other known characteristics of dormancy (<xref ref-type="bibr" rid="bib60">Shepherd and Dick, 2022</xref>). This suggests that HGSOC spheroids are ideal to search for survival dependencies specific to dormant cells.</p><p>HGSOC is the deadliest gynecologic malignancy, accounting for more than 70% of cases (<xref ref-type="bibr" rid="bib38">Lheureux et al., 2019</xref>). Its poor prognosis is largely attributed to late-stage diagnosis with metastases already present. Metastatic spread is facilitated by multicellular clusters of tumor cells, called spheroids, that are shed into the peritoneal cavity and disseminate to nearby organs (<xref ref-type="bibr" rid="bib36">Lengyel, 2010</xref>). The non-proliferative state of spheroid cells renders them chemoresistant and contributes to disease recurrence, emphasizing the need to understand the biology of these cells (<xref ref-type="bibr" rid="bib5">Bowtell et al., 2015</xref>). Dormant HGSOC cells are characterized by similar metabolic changes, EMT, and cytokine signaling as dormant cancer cells from other disease sites (<xref ref-type="bibr" rid="bib61">Sosa et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Shepherd and Dick, 2022</xref>). Mechanisms that mediate their dormant properties include AMPK-LKB1 signaling that induces autophagy (<xref ref-type="bibr" rid="bib51">Peart et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Buensuceso et al., 2020</xref>), STAT3 and FAK for survival and chemoresistance (<xref ref-type="bibr" rid="bib13">Chen et al., 2017b</xref>; <xref ref-type="bibr" rid="bib18">Diaz Osterman et al., 2019</xref>), and DYRK1A signaling to arrest proliferation (<xref ref-type="bibr" rid="bib42">MacDonald et al., 2017</xref>). Unfortunately, therapeutic approaches to target these pathways in ovarian cancer have yet to emerge, indicating that more candidates are needed.</p><p>Netrins are a family of secreted factors that reside in the extracellular matrix and were first identified in axon guidance in the developing nervous system (<xref ref-type="bibr" rid="bib55">Rajasekharan and Kennedy, 2009</xref>; <xref ref-type="bibr" rid="bib33">Kryza et al., 2023</xref>). Together with their receptors, Netrins have since been implicated in cancer progression (<xref ref-type="bibr" rid="bib45">Mehlen et al., 2011</xref>). Netrin-1 is the most studied and its misregulation in cancer leads to pro-survival signals (<xref ref-type="bibr" rid="bib2">Arakawa, 2004</xref>). Netrin interactions with DCC and UNC5 homologs (UNC5H, UNC5A-D) convert pro-death signals by these dependence receptors to survival signals (<xref ref-type="bibr" rid="bib6">Brisset et al., 2021</xref>). Netrin signals through PI3K-AKT and ERK-MAPK are known to participate in orientation decisions in development by providing guidance cues (<xref ref-type="bibr" rid="bib25">Forcet et al., 2002</xref>; <xref ref-type="bibr" rid="bib34">Larrieu-Lahargue et al., 2010</xref>; <xref ref-type="bibr" rid="bib65">Yin et al., 2017</xref>), while loss of ligand binding leads DCC or UNC5H to stimulate dephosphorylation of DAPK1 that sends pro-death signals (<xref ref-type="bibr" rid="bib40">Llambi et al., 2005</xref>; <xref ref-type="bibr" rid="bib10">Castets et al., 2009</xref>). The gene encoding DCC is frequently deleted in cancer (<xref ref-type="bibr" rid="bib2">Arakawa, 2004</xref>), and Netrin-1 blocking antibodies are in Phase II clinical trials for endometrial and cervical carcinomas to inhibit metastatic growth (<xref ref-type="bibr" rid="bib6">Brisset et al., 2021</xref>). Alternative receptors for Netrins such as NEO, DSCAM, and Integrins also mediate their signals (<xref ref-type="bibr" rid="bib45">Mehlen et al., 2011</xref>), creating a myriad of possible pathways for Netrins to regulate cancer cells. Lastly, functional roles for Netrin-3,–4, and –5 are still relatively unexplored compared to Netrin-1 (<xref ref-type="bibr" rid="bib7">Bruikman et al., 2019</xref>), although their expression patterns suggest roles in advanced forms of some cancers (<xref ref-type="bibr" rid="bib31">Jiang et al., 2021</xref>). A functional role for Netrins and their receptors in dormancy, or other aspects of HGSOC spheroid biology have yet to be reported.</p><p>In this study, we utilized a suspension culture system to interrogate survival mechanisms in dormancy using HGSOC spheroids. To maximize discovery of gene loss events that compromise viability in dormancy, we devised a novel genome-wide CRISPR screen approach that we term ‘GO-CRISPR’. In addition to the standard CRISPR workflow, GO-CRISPR utilizes a parallel screen in which ‘guide-only’ cells lacking Cas9 are used to control for stochastic changes in gRNA abundance in non-proliferative cells. This screen identified multiple Netrin ligands, DCC, UNC5Hs, and downstream MAPK signaling components as supporting survival of HGSOC cells in dormant culture conditions. A transcriptomic analysis of HGSOC spheroids also revealed Netrin signaling components were enriched in HGSOC spheroids compared to adherent cells, and that in the absence of the DYRK1A survival kinase Netrin transcriptional increases were lost. We show that multiple Netrins, UNC5 receptors, and the downstream MEK-ERK axis is crucial for survival signaling in dormant cell culture. Importantly, Netrin activation of ERK is restricted to spheroid cultures and is unable to stimulate proliferation, consistent with its role in dormant survival. We blocked Netrin signaling by deleting UNC5 receptors and using xenograft approaches demonstrated that loss of Netrin signaling compromises survival of HGSOC cells, specifically in the dormant stage of dissemination. Furthermore, we show that overexpression of Netrin-1 and –3 are associated with poor prognosis in HGSOC and their overexpression in culture increases survival in suspension culture. Netrin overexpression in xenografts contributes to increased disease dissemination in a model of metastasis. Our study highlights Netrin-ERK signaling as a requirement for spheroid survival and suggests it may be a potential therapeutic target for eradicating dormant HGSOC cells.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Axon guidance genes are essential factors for HGSOC spheroid viability</title><p>To dissect genetic dependencies of dormant ovarian cancer cells, we utilized a suspension culture system that encourages cellular aggregation, leading to non-proliferative spheroids that resemble dormant aggregates found in ovarian cancer patient ascites (<xref ref-type="bibr" rid="bib14">Correa et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">MacDonald et al., 2017</xref>; <xref ref-type="bibr" rid="bib60">Shepherd and Dick, 2022</xref>; <xref ref-type="bibr" rid="bib59">Shepherd et al., 2006</xref>). <xref ref-type="fig" rid="fig1">Figure 1A</xref> illustrates withdrawal from cellular proliferation by HGSOC cells in suspension as evidenced by reduced expression of Ki67 and increased expression of the quiescence marker p130 (<xref ref-type="bibr" rid="bib39">Litovchick et al., 2004</xref>). Furthermore, phospho-western blots for ERK demonstrate reduced but not absent phosphorylation, and phospho-p38 either remains consistent or is increased. Reduced phospho-ERK and elevated phospho-p38 are indicative of the characteristic signaling switch reported to underlie most paradigms of cancer cell dormancy (<xref ref-type="bibr" rid="bib27">Goddard et al., 2018</xref>). These findings are relatively consistent among the three HGSOC cell lines; iOvCa147, OVCAR8, TOV1946 selected for use in our screen. To discover genes required for survival in spheroids, we utilized a new approach called GO-CRISPR (Guide Only CRISPR) that we developed specifically for survival gene discovery in three-dimensional spheroid cell culture conditions (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). GO-CRISPR incorporates sgRNA abundances from non-Cas9-expressing cells to control for stochastic (non-Cas9 dependent) effects that are a challenge in three-dimensional culture conditions with slow or arrested proliferation (<xref ref-type="bibr" rid="bib66">Zanoni et al., 2016</xref>). We used sequencing to determine sgRNA identity and abundance in the library, initially infected cells, and in cells following 48 hr of suspension culture (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Read count data was analyzed using a software package that we developed to analyze GO-CRISPR data (summarized in <xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>). We selected genes that had a Spheroid/Adherent Enrichment Ratio (ER) less than 1 (p&lt;0.05) because some genes become depleted in adherent growth before being transferred to suspension culture conditions and this ratio selects for genes with a stronger effect in suspension when cells are not proliferating (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). To assess reliability of screen data, we investigated the classification of non-targeting control sgRNAs. We computed a receiver operator characteristic curve (ROC) and determined the area under the curve for each cell line (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Greater than 95% of sgRNAs in iOVCA147 and OVCAR8 screens were classified as non-essential, while 83% of sgRNAs in TOV1946 cells were non-essential. In addition, we compared GO-CRISPR screen ER values with viability data from siRNA knock down for 35 individual genes we have previously studied in spheroid survival assays in OVCAR8 and iOVCA147 cells (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>; <xref ref-type="bibr" rid="bib42">MacDonald et al., 2017</xref>). This revealed a statistically significant correlation between the two sets of data, suggesting that genes we previously knew supported spheroid viability (or were dispensable) were classified similarly by our screen. These controls suggested our screen data was reliable for identifying new survival dependencies.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>GO-CRISPR screens implicate axon guidance pathways as supporting HGSOC spheroid cell viability.</title><p>(<bold>A</bold>) iOvCa147, TOV1946, or OVCAR8 cells were cultured under adherent conditions (Adh) or in suspension to induce spheroid formation (Sph). Lysates were prepared and analyzed by western blotting for the proliferation marker Ki67 and the quiescence marker p130, and phosphorylated and total levels of ERK and p38. Tubulin was blotted as a loading control. (<bold>B</bold>) Flow chart of GO-CRISPR screening used for each of iOvCa147, TOV1946, or OVCAR8 control cells and derivatives of each that express Cas9. Cas9-positive cells (top row) and Cas9-negative cells (bottom row) were transduced with the GeCKO v2 pooled sgRNA library. After antibiotic selection, cells were expanded under adherent culture conditions (0 hr) before being transferred to suspension culture conditions to induce spheroid formation and select for cell survival. After 48 hr, spheroids were transferred to standard plasticware to isolate viable cells. Red arrows indicate the relevant comparisons of sgRNA sequence abundance that were made to analyze screen outcomes. Genes with relatively greater effect on viability in suspension were selected by comparing their scores between adherent and suspension conditions and considering genes with an enrichment ratio (ER) of &lt;1. (<bold>C</bold>) Scatter plots representing the spheroid score on y-axis and adherent score on the x-axis calculated by TRACS for each gene in each cell line (iOvCa147, TOV1946, OVCAR8). Colored data points represent genes with ER &lt;1 and p<sub>adj</sub> &lt;0.05 (paired t-test). (<bold>D</bold>) Venn diagram illustrating overlap of genes identified as supporting cell viability in suspension culture from iOvCa147, TOV1946, and OVCAR8 cells. (<bold>E</bold>) Graph depicting enriched pathways from ConsensusPathDB using the 1382 commonly identified genes from D. Categories are ranked by q-value. Tiers of Reactome categories are indicated by shading.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original files for western blot analysis in <xref ref-type="fig" rid="fig1">Figure 1A</xref> (Ki67, p130, pERK T202/Y204, ERK, p38 T180/Y182, p38, Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91766-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>PDF containing annotation of original western blots in <xref ref-type="fig" rid="fig1">Figure 1A</xref> (Ki67, p130, pERK T202/Y204, ERK, p38 T180/Y182, p38, Tubulin).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91766-fig1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>CRISPR screen analysis details and internal controls.</title><p>(<bold>A</bold>) Flowchart of data analysis used to identify genes that are most relevant to ovarian cancer cell survival in suspension. (<bold>B</bold>) Mathematical formulas to define gene scores, enrichment scores (n=guides per gene), and enrichment ratios used by TRACS. (<bold>C</bold>) Reader-operator curves were generated to assess TRACS categorization of 1000 non-targeting control sgRNAs in the GeCKOv2 library for each of the three cell lines screened. (<bold>D</bold>) Spheroid cell viability levels from low throughput siRNA gene knock downs for 35 genes in iOvCa147 and OVCAR8 cells was plotted against the enrichment ratio for the same genes in the same two cell lines from this screen. These independent approaches to measure viability were compared using linear regression.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Numerical data used in the graph in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig1-figsupp1-v1.tif"/></fig></fig-group><p>We found 6,717 genes with an ER below 1 in iOvCa147 cells; and 7,637 genes in TOV1946; and 7,640 genes in OVCAR8 cells. Among these genes; 1382 were common to all three cell lines (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). We performed pathway enrichment analysis on these common genes and identified several significantly enriched pathways. These include primary and secondary Reactome gene sets such as signal transduction, metabolism, and signaling by GPCR (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). In addition, we identified a tertiary category called ‘axon guidance,’ that includes numerous components of the Netrin signaling pathway that scored highly.</p></sec><sec id="s2-2"><title>Expression of Netrin ligands and receptors are enriched in HGSOC spheroids</title><p>DYRK1A was previously discovered to support survival of ovarian cancer cells in suspension culture (<xref ref-type="bibr" rid="bib42">MacDonald et al., 2017</xref>). Since DYRK1A phosphorylates RNA polymerase II in transcription initiation (<xref ref-type="bibr" rid="bib19">Di Vona et al., 2015</xref>), we sought to determine if it regulates gene expression in spheroid survival. We created <italic>DYRK1A<sup>-/-</sup></italic> iOvCa147 cells and confirmed their deficiency for survival in suspension (<xref ref-type="fig" rid="fig2">Figure 2</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–E</xref>). Using iOvCa147 and <italic>DYRK1A<sup>-/-</sup></italic> derivatives, we performed RNA-seq on adherent and spheroid cells. We collected spheroids following a 6 hr incubation in suspension because overexpression of known cell cycle transcriptional targets due to DYRK1A loss were first evident at this time point, but loss of viability due to DYRK1A deficiency had not yet occurred (<xref ref-type="bibr" rid="bib42">MacDonald et al., 2017</xref>). We compared iOvCa147 adherent cells to 6 hr suspension culture to identify transcriptional changes that occur as these cells transitioned from adherent conditions to suspension conditions (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We identified 1834 genes that were upregulated, and pathway enrichment analysis identified many of the same categories as our CRISPR screen including axon guidance (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). We then compared iOvCa147 spheroid cells to <italic>DYRK1A<sup>-/-</sup></italic> spheroid cells to identify mRNA expression changes that were lost through DYRK1A deficiency (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). We identified 744 genes that were downregulated and these also belonged to many of the same pathways, including axon guidance (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Axon guidance pathway components are upregulated in iOvCa147 spheroid cells in a DYRK1A dependent manner.</title><p>(<bold>A</bold>) RNA was isolated from iOvCa147 cells following culture under adherent conditions or in suspension conditions to induce spheroid formation for 6 hr. Triplicate independent cultures were processed for RNA-seq. A volcano plot shows differentially expressed genes in spheroid cells compared to adherent. 1937 genes were found to be downregulated in iOvCa147 spheroid cells (log<sub>2</sub> fold change &lt;1, p<sub>adj</sub> &lt;0.05 (Wald test), FDR 10%, highlighted in grey) and 1,834 genes were upregulated (log<sub>2</sub> fold change &gt;1, p<sub>adj</sub> &lt;0.05, FDR 10%, highlighted in blue). (<bold>B</bold>) Top 15 most significantly enriched pathways (p<sub>adj</sub> &lt;0.05) whose genes were upregulated in suspension culture compared to adherent in RNA-seq analysis. (<bold>C</bold>) A volcano plot showing differentially expressed genes in <italic>DYRK1A<sup>-/-</sup></italic> spheroid cells compared to iOvCa147 spheroid cells. A ttoal of 744 genes were found to be downregulated in <italic>DYRK1A<sup>-/-</sup></italic> spheroid cells (log<sub>2</sub> fold change &lt;1, p<sub>adj</sub> &lt;0.05 (Wald test), FDR 10%, highlighted in red) and 96 genes were upregulated (log<sub>2</sub> fold change &gt;1, p<sub>adj</sub> &lt;0.05 (Wald test), FDR 10%, highlighted in grey). (<bold>D</bold>) Top 15 most significantly enriched pathways that were represented by downregulated genes in <italic>DYRK1A<sup>-/-</sup></italic> suspension culture compared to control cells in suspension. (<bold>E</bold>) Venn diagram depicting overlapping enriched pathways identified in GO-CRISPR screens in green; enriched pathways identified in upregulated genes in parental iOvCa147 spheroid cells in blue; and enriched pathways identified in downregulated genes in <italic>DYRK1A<sup>-/-</sup></italic> spheroid cells in red. 78 pathways were commonly enriched in all three datasets (shown in yellow). (<bold>F</bold>) Top 10 most significantly enriched pathways among the 78 identified in C.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Generation of iOvCa147 cells deficient for DYRK1A and loss of viability in suspension.</title><p>(<bold>A</bold>) Strategy to generate <italic>DYRK1A<sup>-/-</sup></italic> cells using a pair of sgRNAs that flank exon 2. PCR For and PCR Rev primers flank exon 2 and are used to detect deletion events. (<bold>B</bold>) Agarose gel showing PCR products for iOVCA147 cells and putative <italic>DYRK1A<sup>-/-</sup></italic> cells. The full length amplicon containing exon 2 was detected in parental iOvCa147 cells (1348 bp). A smaller amplicon (1026 bp) was detected in <italic>DYRK1A<sup>-/-</sup></italic> cells, indicting successful excision of the 322 bp region encompassing exon 2. (<bold>C</bold>) Western blot comparing DYRK1A expression in iOVCA147 cells and <italic>DYRK1A<sup>-/-</sup></italic> cells. (<bold>D</bold>) IP kinase assay to evaluate DYRK1A activity in <italic>DYRK1A<sup>-/-</sup></italic> cells. Anti-DYRK1A antibodies or IgG was used to immunoprecipitate from iOVCA147 and <italic>DYRK1A<sup>-/-</sup></italic> cells. Precipitates were incubated with ATP and Tau protein. Samples were resolved by SDS-PAGE and probed with pSer404-Tau antibody. (<bold>E</bold>) Parental iOvCa147 or <italic>DYRK1A<sup>-/-</sup></italic> cells were incubated in suspension conditions for 24 hr, 72 hr, or 4 days to induce spheroid formation, and then re-plated in adherent conditions for 24 hr to allow reattachment. Reattached spheroid cells were stained with crystal violet and absorbance was quantified. Alternatively, cells in suspension were isolated and utilized for Cell TitreGLO cell viability measurements. <italic>DYRK1A<sup>-/-</sup></italic> spheroid cells had impaired survival compared to parental iOvCa147 spheroid cells at each time point and reattached and crystal violet stained cell viability matched Cell TitreGLO measurements of viability (one-way anova, ****p&lt;0.0001).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Original files for western blot analysis in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and D</xref> – (DYRK1A, pTAU S404, TAU, Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91766-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>PDF containing annotation of original western blots in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and D</xref> – (DYRK1A, pTAU S404, TAU, Tubulin).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91766-fig2-figsupp1-data2-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata3"><label>Figure 2—figure supplement 1—source data 3.</label><caption><title>Numerical data used in the graph in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig2-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig2-figsupp1-v1.tif"/></fig></fig-group><p>We compared enriched pathways from these two RNA-seq analyses with those that were identified in our GO-CRISPR screens to identify gene expression programs in spheroids whose products are essential for cell survival. 78 Reactome pathways were commonly enriched across the GO-CRISPR screens and transcriptomic analyses, including 78 of the 83 pathways identified in RNA-seq from <italic>DYRK1A<sup>-/-</sup></italic> spheroid cells (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). The axon guidance pathway was one of the most enriched among these common pathways (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). These data reveal that our GO-CRISPR screen and transcriptomic analyses converge on this highly specific tertiary Reactome category of axon guidance alongside much broader primary or secondary gene sets. This category includes Netrin ligands, receptors, and downstream signaling components, suggesting a previously unappreciated role in HGSOC spheroid viability.</p><p>We separately sought to confirm elevated expression of Netrins and some of their signaling components in HGSOC spheroid cell culture. We examined expression levels of ligands and receptors in the three cell lines used in our GO-CRISPR screen using RT- qPCR (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref>). The precise identities of upregulated genes varies between cell lines; however, each cell line increases expression of some Netrins, at least one UNC5, and at least one of DCC, DSCAM, and Neogenin. This suggests that the Netrin pathway components are expressed in HGSOC cells may play a previously unappreciated role in dormancy and disease progression.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Expression of Netrin ligands and their dependence receptors is increased in suspension culture.</title><p>(<bold>A–C</bold>) RT-qPCR was performed to quantitate mRNA expression levels of Netrin ligands and receptors in three different HGSOC cell lines. Relative expression of the indicated transcripts is shown for suspension culture conditions compared with adherent. All experiments were performed in at least triplicate biological replicates. Means were compared with the same gene in adherent culture using a one way anova (*p&lt;0.05, ****p&lt;0.0001).</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Numerical data used in the graph in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig3-v1.tif"/></fig><p>Since Netrin signaling has not been previously associated with dormancy we examined expression of Netrin-1 and –3 ligands in spheroids isolated directly from patient ascites by immunohistochemistry. First, we assessed proliferative markers in HGSOC tumor tissue and spheroids by staining for Ki67 and p130. As expected, solid HGSOC tumors display uniform Ki67 positivity and relative absence of p130 (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). Conversely, serial sections of spheroids demonstrated rare Ki67 nuclear staining and abundant and uniform p130 staining. This indicates that cells in these patient derived spheroids are quiescent (<xref ref-type="fig" rid="fig4">Figure 4C–E</xref>). To investigate the presence of Netrins, we initially tested Netrin-1 and –3 antibody specificity using spheroids generated from OVCAR8 cells bearing knock out or over expression of Netrins (<xref ref-type="fig" rid="fig4">Figure 4</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–F</xref>). Dormant patient derived spheroids were stained for Netrins and epithelial markers Cytokeratin and EpCAM. Since HGSOC is characterized by point mutations in p53 and its accumulation in the nucleus, sections were also stained for p53 to confirm cancer cell identity within these spheroids by high level nuclear staining (<xref ref-type="fig" rid="fig4">Figure 4F–H</xref>). Overall, this confirms Netrin expression occurs in dormant HGSOC patient spheroids, precisely the context our screen indicates that they are critical for cell survival.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Netrins are expressed in dormant patient derived spheroids.</title><p>Spheroids were isolated from ascites of HGSOC patients and processed for immunohistochemical staining. (<bold>A–B</bold>) Serial sections from solid HGSOC tumors were stained with antibodies to p130, Ki67, or a no primary antibody control (NP). Scale bar = 100 μm for upper panels and 2 mm for lower panels. (<bold>C–E</bold>) Serial spheroid sections from the indicated patients were stained with Ki67 and p130. Sections with dense positive nuclear staining are indicated with white arrows. Scale bar = 100 μm. (<bold>F–H</bold>). Immunohistochemical staining was performed for the indicated proteins on serial sections of ascites derived spheroids. Omission of primary antibody was used a control for background staining for each patient sample (NP). Scale bar = 100 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Specificity of Netrin-1 and Netrin-3 IHC staining of OVCAR8 spheroids.</title><p>(<bold>A</bold>) OVCAR8 cells were allowed to form spheroids for 6 hr before fixation in formalin and embedding in paraffin for sectioning. Serial sections were stained with Netrin-1 Abs or a no primary antibody control. (<bold>B</bold>) OVCAR8 cells overexpressing Netrin-1 were used to prepare spheroids as in A and stained in parallel to samples in A. (<bold>C</bold>) OVCAR8 deleted for Netrin-1 expression were used to prepare spheroids as in A and serial sections were stained for Netrin-1 or with a no primary antibody control and counter stained. (<bold>D</bold>) OVCAR8 cells were allowed to form spheroids for 6 hr before fixation in formalin and embedding in paraffin for sectioning. Serial sections were stained with Netrin-3 Abs or a no primary antibody control. (<bold>E</bold>) OVCAR8 cells overexpressing Netrin-3 were used to prepare spheroids as in D and stained in parallel to samples in D. (<bold>F</bold>) OVCAR8 deleted for Netrin-3 expression were used to prepare spheroids as in D and serial sections were stained for Netrin-3 or with a no primary antibody control. All scale bars = 100 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Netrin signaling stimulates ERK to support HGSOC spheroid survival</title><p>Netrin ligands and their dependence receptors are best known for their roles in axon guidance (<xref ref-type="bibr" rid="bib46">Meijers et al., 2020</xref>), but are appreciated to regulate apoptosis in cancer (<xref ref-type="bibr" rid="bib45">Mehlen et al., 2011</xref>). <xref ref-type="fig" rid="fig5">Figure 5A</xref> illustrates components of Netrin signaling and the frequency with which they were discovered to have an ER of &lt;1 in our screens. In addition, intracellular signaling molecules known to be downstream of Netrin receptors that are shared with other enriched pathways identified in our screens, are also illustrated. To confirm screen findings, we independently knocked out <italic>NTN1</italic>, <italic>NTN3</italic>, <italic>NTN4</italic>, <italic>NTN5</italic>, the UNC5H receptor homologs (<italic>UNC5A</italic>, <italic>UNC5B</italic>, <italic>UNC5C</italic>, and <italic>UNC5D</italic>), as well as <italic>DCC</italic>, <italic>DSCAM</italic>, and <italic>NEO1</italic> alone or in multigene combinations using lentiviral delivery of sgRNAs and Cas9 (<xref ref-type="fig" rid="fig5">Figure 5</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–C</xref>). We assessed the effect of their loss on spheroid survival in six HGSOC cell lines (iOvCa147, TOV1946, OVCAR3, OVCAR4, OVCAR8, and COV318). Loss of at least one Netrin ligand resulted in reduced spheroid cell survival in five of six cell lines (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Notably, Netrin-3 loss showed the most pronounced effect on survival. Cell lines such as OVCAR8 and COV318 were relatively resistant to the deletion of Netrin pathway components as individual UNC5, <italic>DCC</italic>, and <italic>DSCAM</italic> genes rarely affected viability (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In these instances, combined deletions of UNC5 family members, or <italic>DCC;DSCAM;NEO1</italic> (DDN for short) were either inviable or highly sensitive to suspension culture induced cell death, suggesting redundancy in this pathway in some cell lines. Other cell lines, such as OVCAR3, were highly sensitive to the loss of multiple individual ligands and any individual UNC5H receptor was highly sensitizing to death induction in suspension (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Overall, these illustrate a robust role for Netrins in survival in this dormant cell culture assay. Importantly, loss of receptor expression does not elevate viability as expected for a dependence receptors, nor does it induce DAPK1 dephosphorylation (<xref ref-type="fig" rid="fig5">Figure 5</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>), suggesting that Netrin receptors in HGSOC spheroids transmit positive survival signals.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Netrin ligands and their receptors are required for spheroid cell survival.</title><p>(<bold>A</bold>) Illustration of netrin ligands, receptors, and other intracellular signaling molecules that are included in the Axon Guidance pathway category. The frequency of their identification in CRISPR screens is illustrated by shading and indicates how many cell lines had an enrichment ratio &lt;1 for a given component. (<bold>B</bold>) The indicated ovarian cancer cell lines were infected with lentiviruses expressing sgRNAs directed against the indicated Netrin signaling genes. Cells were transferred to suspension culture conditions to induce spheroid formation for 72 hr and then returned to adherent conditions for 24 hr to facilitate reattachment. Re-attached cells were stained with Crystal Violet and retained dye was extracted and quantitated to measure relative survival. Each cell-gene combination was assayed in at least three biological replicates, averaged, and viability is displayed as a bubble plot. Mean survival for a given cell-gene combination was compared with GFP control gRNA transduced cells using one way anova and significance levels are illustrated by bubble size. Inviable cell-gene combinations are depicted as empty spaces. (<bold>C</bold>) Cultures of the indicated cell lines were cultured in suspension for five days and stimulated with 0.5 μg/mL Netrin-1. Netrin-1 signaling was analyzed by SDS-PAGE and western blotting for phospho-ERK, ERK, and tubulin. (<bold>D</bold>) Quiescent adherent OVCAR8 cells were stimulated with 0.5 μg/mL Netrin-1 or 0.5 μg/mL EGF, and compared with OVCAR8 cells in suspension stimulated as in C. Extracts were prepared and blotted for phospho-ERK, ERK, and tubulin. (<bold>E</bold>) Suspension cultures of OVCAR8, or knock out derivatives, were harvested and analyzed for relative phosphorylation levels of ERK by western blotting. Total ERK and tubulin blotting serve as expression and loading controls. (<bold>F</bold>) Netrin-1 signaling in OVCAR8, UNC5 4KO and DDN 3KO derivatives was tested by transferring cells to suspension and stimulating with Netrin-1 as before. Western blotting for phospho-ERK, ERK were also as before. (<bold>G</bold>) OVCAR8 cells were seeded in suspension culture and treated with the MEK inhibitors PD184352, Trametinib or DMSO vehicle for 72 hr. Mean viability was determined by re-attachment and compared by one way anova (****p&lt;0.0001). (<bold>H</bold>) OVCAR8 cells were cultured in suspension and treated with Trametinib or DMSO vehicle as in G. Viability was determined by trypan blue dye exclusion and compared by one way anova (**p&lt;0.01). (<bold>I</bold>) Extracts were prepared from Trametinib and control treated spheroid cells and blotted for phospho-ERK, ERK, and tubulin. (<bold>J</bold>) Model summarizing the roles of Netrin ligands, receptors, and downstream targets MEK and ERK in dormant survival signaling.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Numerical data used for bubble plot in <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Original files for western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5C</xref> (pERK T202/Y204, ERK, Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91766-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>PDFs containing annotation of original western blots in <xref ref-type="fig" rid="fig5">Figure 5C</xref> (pERK T202/Y204, ERK, Tubulin).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91766-fig5-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Original files for western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5D</xref> (pERK T202/Y204, ERK, Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91766-fig5-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>PDFs containing annotation of original western blots in <xref ref-type="fig" rid="fig5">Figure 5D</xref> (pERK T202/Y204, ERK, Tubulin).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91766-fig5-data5-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata6"><label>Figure 5—source data 6.</label><caption><title>Original files for western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5E</xref> (pERK T202/Y204, ERK, Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91766-fig5-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata7"><label>Figure 5—source data 7.</label><caption><title>PDFs containing annotation of original western blots in <xref ref-type="fig" rid="fig5">Figure 5E</xref> (pERK T202/Y204, ERK, Tubulin).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91766-fig5-data7-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata8"><label>Figure 5—source data 8.</label><caption><title>Original files for western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5F</xref> (pERK T202/Y204, ERK).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91766-fig5-data8-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata9"><label>Figure 5—source data 9.</label><caption><title>PDFs containing annotation of original western blots in <xref ref-type="fig" rid="fig5">Figure 5F</xref> (pERK T202/Y204, ERK).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91766-fig5-data9-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata10"><label>Figure 5—source data 10.</label><caption><title>Numerical data used for graphs in <xref ref-type="fig" rid="fig5">Figure 5G and H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig5-data10-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata11"><label>Figure 5—source data 11.</label><caption><title>Original files for western blot analysis in <xref ref-type="fig" rid="fig5">Figure 5E</xref> (pERK T202/Y204, ERK, Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91766-fig5-data11-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata12"><label>Figure 5—source data 12.</label><caption><title>PDFs containing annotation of original western blots in <xref ref-type="fig" rid="fig5">Figure 5E</xref> (pERK T202/Y204, ERK, Tubulin).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91766-fig5-data12-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Evaluation of target gene transcript levels in multigene knock out cells.</title><p>(<bold>A</bold>) RT-qPCR was performed on RNA isolated from control sgRNA expressing OVCAR8 cells and UNC5 4KO to assess expression of UNC5 family members. Graphs depict relative expression levels for each indicted gene in control and knock out cell lines. Mean expression levels of targeted cells were compared to background measurements using one way anova (****p&lt;0.0001). (<bold>B</bold>) RT-qPCR was used to measure mRNA levels of NTN1 and NTN3 transcripts in their respective CRISPR targeted, and OVCAR8 controls. Mean values were compared by one way anova (****p&lt;0.0001). (<bold>C</bold>) Levels of mRNA corresponding to DCC, DSCAM, and NEO1 were determined by RT-qPCR in DDN 3KO cells and control OVCAR8. Mean values were compared by one way anova (****p&lt;0.0001). (<bold>D</bold>) The indicated genotypes of cells were subjected to suspension culture and protein extracts were prepared at the indicated times. Proteins were resolved by SDS-PAGE, blotted, and probed with the indicated antibodies.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Numerical data used for graphs in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref> (pDAPK1 S318, DAPK1, Tubulin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91766-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata3"><label>Figure 5—figure supplement 1—source data 3.</label><caption><title>PDF containing annotation of original western blots in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref> (pDAPK1 S318, DAPK1, Tubulin).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91766-fig5-figsupp1-data3-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig5-figsupp1-v1.tif"/></fig></fig-group><p>To determine if Netrin dependent signaling is active in HGSOC spheroids, we stimulated cells in suspension with recombinant Netrin-1 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Western blotting for phospho-ERK, as a measure of activation, revealed stimulation of MEK-ERK signaling in each of the cell lines tested. Because MAPK signaling is best known for its role in proliferation, we also tested Netrin-1 stimulation of quiescent, adherent cells and compared this with stimulation in spheroid culture. Both conditions display similar, low levels of phospho-ERK, but Netrin-1 was only able to stimulate ERK phosphorylation in suspension (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Importantly, stimulation of adherent cells with an equivalent concentration of EGF induced pERK levels commonly seen in proliferating cells. Collectively, the context and magnitude of pERK stimulation by Netrin-1 is inconsistent with proliferative signaling, suggesting it may contribute to survival. This suggested that Netrin is a candidate pathway to provide low level, but essential survival signals through the MAPK pathway in dormant spheroids. We investigated the dependence of ERK phosphorylation on UNC5H and DDN receptors and discovered that it is lower when receptors are deleted (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Furthermore, Netrin-1 stimulation of suspension cultures of OVCAR8 cells, or derivatives deleted for UNC5 family members or DDN receptors, indicated that Netrin receptors are essential to activate ERK in suspension culture (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). To confirm that Netrin-MEK-ERK signaling contributes to survival in suspension culture, we used two different MEK inhibitors, PD184352 and Trametinib, to treat OVCAR8 suspension cultures and observed that it causes loss of cell viability in suspension culture (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Since we routinely use reattachment of spheroids to adherent plastic as a test of viability, also tested viability using trypan blue dye exclusion to confirm that Trametinib is truly killing cells in suspension and it revealed the same conclusion (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). As expected, treatment of cells in suspension with Trametinib lead to lower phospho-ERK levels (<xref ref-type="fig" rid="fig5">Figure 5I</xref>). The simplest explanation of this data is that Netrins signal through a heterodimer or multi-receptor complex containing both an UNC5 and DDN component that provides low level stimulation for MEK and ERK specifically in dormant culture conditions.</p></sec><sec id="s2-4"><title>Netrin signaling is essential for dormant spheroid survival during metastatic dissemination</title><p>To investigate the role of Netrin signaling in the context of residual disease and relapse, we xenografted mice with control OVCAR8L cells, or UNC5 4KO cells, by intraperitoneal injection (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Two weeks following injection, mice were euthanized, and spheroids were obtained by washing the abdominal cavity with PBS. Importantly, at this early stage of engraftment, solid tumor lesions were not yet observable, indicating that we are modeling minimal residual disease where dormancy is most relevant. Extraction of RNA from control OVCAR8 cell spheroids recovered at this time point indicates a reduction in expression of pro-proliferative genes compared to the same cells prior to engraftment (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Furthermore, comparison with RT-qPCR measurements of these same markers in suspension culture induced OVCAR8 spheroids indicates that spheroids from abdominal washes are equivalently withdrawn from the cell cycle (<xref ref-type="fig" rid="fig6">Figure 6</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). This suggests spheroids at this stage are dormant. Furthermore, recovery of spheroids by replating on adherent plastic indicates that deletion of UNC5 receptors to block Netrin signaling extensively reduces survival under these circumstances (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). We also quantitated cancer cells in these abdominal washes by qPCR using human Alu repeat detection to count cells and this also demonstrates that cancer cell abundance is reduced in this dormant state by loss of UNC5 receptors. Further xenografts were performed to investigate the long term consequences of reduced survival of UNC5 4KO cells in mice. This demonstrated that mice engrafted with UNC5 4KO cells had a considerably longer survival than control OVCAR8 recipient mice that received the same number of cells (<xref ref-type="fig" rid="fig6">Figure 6E and F</xref>). Collectively, this demonstrates that inhibition of Netrin signaling compromises viability and eventual disease progression in a model of dormancy and dissemination.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Loss of Netrin signaling reduces spheroids and prolongs survival.</title><p>(<bold>A</bold>) Control OVCAR8L (negative control CRISPR targeted cells) and UNC5 4KO cells were injected into the peritoneal space of female NOD/SCID mice. After 2 weeks, animals were euthanized and engrafted cells were collected with abdominal washes. (<bold>B</bold>) RT-qPCR was used to compare gene expression of the indicated cell cycle markers in RNA extracted from proliferating cells in culture before engraftment and compared with RNA obtained from spheroids in xenografted mice. Technical replicates of RNA derived from three different mice is shown. (<bold>C</bold>) Spheroids obtained from abdominal washes from each mouse were plated in adherent conditions to compare their abundance between control and UNC5 4KO genotypes. One example of each genotype of cell is shown. Crystal violet staining and dye extraction were used to quantitate biomass and averages were compared by one-way anova (n=6, *p&lt;0.05). (<bold>D</bold>) DNA was extracted from cells collected in abdominal washes and human Alu repeats were detected by qPCR to quantitate and compare human cancer cells. Means were compared by one-way anova (n=6, **p&lt;0.01). (<bold>E</bold>) Control OVCAR8 and UNC5 4KO cells were xenografted as above and mice were monitored until humane endpoint. (<bold>F</bold>) Kaplan-Meier analysis of survival for mice engrafted with the indicated genotypes of cells. Survival was compared by logrank test.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Numerical data used for graphs in <xref ref-type="fig" rid="fig6">Figure 6B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig6-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Numerical data used for graphs in <xref ref-type="fig" rid="fig6">Figure 6C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig6-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Numerical data used for graphs in <xref ref-type="fig" rid="fig6">Figure 6D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig6-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><label>Figure 6—source data 4.</label><caption><title>Numerical data used for graphs in <xref ref-type="fig" rid="fig6">Figure 6F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig6-data4-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Evaluation of dormancy arrest in cell culture by RT-qPCR.</title><p>RNA was extracted from asynchronously proliferating cells and suspension cultures 72 hr post transfer from adherent. RT-qPCR was used to compare gene expression of the indicated cell cycle markers in iOvCa147, OVCAR8, TOV1946.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Numerical data used for graphs in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Netrin overexpression is correlated with poor outcomes in HGSOC</title><p>Genomic studies indicate that HGSOC is one of the most aneuploid cancers (<xref ref-type="bibr" rid="bib48">Network CGA, 2011</xref>). In addition to the frequency of copy number variants per tumor, the locations of gains and losses are dissimilar between cases, making this a highly heterogenous disease. Evaluation of TCGA genomic data for HGSOC indicates rare amplifications or deletions of Netrin or Netrin-receptor genes (<xref ref-type="fig" rid="fig7">Figure 7</xref>; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). Because of redundancy of Netrins and their receptor families this data suggests HGSOC cases with deficiency for Netrin signaling are rare. This is consistent with our data that all six cell lines tested reveal evidence of Netrin component dependence for survival (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Some TCGA HGSOC cases display elevated gene expression for Netrins or their receptors, but only rare cases display low expression (<xref ref-type="fig" rid="fig7">Figure 7</xref>; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). This suggests that Netrin signaling in HGSOC is retained despite high copy number variation in this cancer type and there is occasional overexpression.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Netrin ligand overexpression is associated with poor clinical outcome in HGSOC.</title><p>(<bold>A</bold>) TCGA RNA-seq data for HGSOC patients (TCGA PanCancer Atlas study) was used to identify high Netrin-1 or –3 and low Netrin-1 or –3 expressing patients (high expressing are above z-score 1.2). Overall survival was used to construct Kaplan-Meier plots and survival was compared using a logrank test. (<bold>B</bold>) OVCAR8 cells were stably transduced with lentiviral constructs to overexpress epitope tagged Netrin-1 or –3. Western blotting for Netrins, Myc-tags, and Actin were used to determine relative expression levels of both Netrins in these cell populations and vector controls. (<bold>C</bold>) Control and Netrin overexpressing cells were transferred to suspension culture conditions to form spheroids, and replated to assay for viability. Mean viability and standard deviation is shown for each. One-way anova was used to compare survival (* p&lt;0.05, *** p&lt;0.001). (<bold>D</bold>) Reattached spheroids were fixed and stained with Crystal Violet to examine size and abundance in control and Netrin-1 or –3 overexpression.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Original files for western blot analysis in <xref ref-type="fig" rid="fig7">Figure 7B</xref> (Myc, Netrin-1, Netrin-3, Actin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91766-fig7-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>PDFs containing annotation of original western blot analysis in <xref ref-type="fig" rid="fig7">Figure 7B</xref> (Myc, Netrin-1, Netrin-3, Actin).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91766-fig7-data2-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig7sdata3"><label>Figure 7—source data 3.</label><caption><title>Numerical data used for graphs in <xref ref-type="fig" rid="fig7">Figure 7C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig7-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Frequency of Netrin ligand and receptor deletions, mutations or expression changes in high grade serous ovarian cancer.</title><p>(<bold>A</bold>) Oncoprint of genetic alterations in 10 netrin signaling related genes in 398 patients. Alteration types are defined on the right. Only the first 154 patients are shown. (<bold>B</bold>) Oncoprint illustrating gene expression outliers among 10 netrin signaling related genes in 201 patients (first 122 patients shown). Genomic data used is from Ovarian Serous Cystadenocarcinoma (TCGA, PanCancer Atlas) (201 samples with RNA seqV2, z-score cut off of 1.5). (<bold>C</bold>) TCGA RNA-seq data for HGSOC patients (TCGA PanCancer Atlas study) was used to identify high Netrin-1 or –3 and low Netrin-1 or –3 expressing patients (high expressing are above z-score 1.2). Progression free survival was used to construct Kaplan-Meier plots and survival was compared using a logrank test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig7-figsupp1-v1.tif"/></fig></fig-group><p>In agreement with our experimental data that multiple Netrin ligands can contribute to spheroid survival in HGSOC (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>), sorting cases by high level expression of Netrin-1 and –3 ligands reveals a significantly shorter overall survival compared to cases with low level expression and this trend is also evident in the cases that only overexpress Netrin-3 (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). This genomic data supports the interpretation that Netrin signaling is retained in HGSOC and its elevation is deleterious to patient outcome.</p><p>We investigated overexpression of Netrin-1 and –3 in spheroid survival by generating OVCAR8 derivatives that stably overexpress these proteins (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). We then utilized these cells in suspension culture assays for spheroid survival as before (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). This data indicates that overexpression of either Netrin-1 or –3 increases OVCAR8 cell survival in dormant spheroid culture conditions. Examination of fixed spheroids isolated from this experiment further indicates that elevated survival in this experiment is explained by an increase in abundance of individual spheroids that overexpress either Netrin-1 or –3 (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). These experiments reveal the significance of a previously undiscovered role for Netrins in HGSOC. High level expression correlates with poor outcome and in suspension culture, overexpression confers oncogenic properties on HGSOC cells.</p></sec><sec id="s2-6"><title>Netrin overexpression induces abdominal spread of HGSOC</title><p>Our findings from CRISPR screens and cell culture experiments indicate that Netrin signaling supports dormant HGSOC cell survival. Our analysis of TCGA is also predictive of a worse outcome for patients. We sought to solidify these findings by searching for how Netrin signaling affects HGSOC disease pathogenesis.</p><p>We utilized a xenograft assay in which OVCAR8 cells overexpressing Netrin-1 or –3 were injected into the peritoneal cavity and compared with OVCAR8 cells bearing an empty vector as control. Mice were harvested following 35 days to analyze disease dissemination and characterize the effect of Netrins in this model of HGSOC metastatic spread (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Necropsy of all animals at endpoint allowed for the identification and quantitation of tumor nodules within the abdomen (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). Petal plots illustrate the frequency of specific organ and tissue sites displaying tumor nodules (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). This revealed that spread to the omentum was similar across all genotypes of xenografted cells and it occurred in all mice (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). In contrast, tumor nodules were detected with increased abundance on the diaphragm, the liver, and mesenteries that support the uterus (mesometrium; <xref ref-type="fig" rid="fig8">Figure 8B</xref>). In addition to more frequent disease spread to these locations caused by Netrin overexpressing cells, we note that the quantity of nodules was also increase in comparison with OVCAR8 control cells (<xref ref-type="fig" rid="fig8">Figure 8C–F</xref>). We confirmed the source of these lesions to be the xenografted cells using immunohistochemical staining for human cytokeratin (<xref ref-type="fig" rid="fig8">Figure 8G and H</xref>). Lastly, Netrin-1 and –3 histochemical staining confirms its presence in the local tumor microenvironment (<xref ref-type="fig" rid="fig8">Figure 8G and H</xref>). The similarity of increased tumor nodules seen in xenografts and elevated spheroid formation and viability seen in culture suggests that Netrin signaling improves cell viability in spheroid aggregates in vivo leading to increased disease spread.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Netrin overexpression causes increased dissemination of tumor nodules.</title><p>(<bold>A</bold>) Netrin overexpressing and control OVCAR8 cells were injected into the intraperitoneal space of female NOD/SCID mice. Mice were euthanized following 35 days and analyzed for disease burden by necropsy and histopathology. (<bold>B</bold>) The spread of cancer to the diaphragm, liver, omentum, and mesometrium was determined from necropsies and colors used in the anatomical schematic correspond with petal plots for each genotype of cells. Petal plot radius illustrates frequency of mice bearing disease spread to a particular location. The radius of color fill is proportional to the total number of animals with tumor nodules found in that location. (<bold>C</bold>) Photographs of necropsy findings in the mesometrium. Locations of ovaries (*), oviduct (yellow arrow), and uterine horn (green arrow) are indicated in each case. Tumor nodules are indicated by white arrows. (<bold>D</bold>) The number of mesometrium associated tumor nodules was determined for each mouse. Mean values are indicated and differences between genotype were determined by one way anova (* p&lt;0.05, ** p&lt;0.01). (<bold>E</bold>) Photographs of necropsy findings in the liver. Location of sternum is indicated (#) in each image. Tumor nodules are indicated by white arrows. (<bold>F</bold>) The number of liver associated tumor nodules was determined for each mouse. Mean values are indicated and differences between genotype were determined by one way anova (** p&lt;0.01, *** p&lt;0.001). (<bold>G</bold> and <bold>H</bold>) Histology of mesometrial tumor nodules are shown. Serial sections were stained with H&amp;E, or with the indicated antibodies for immunohistochemistry. Ovaries are indicated (*), as are the oviduct (yellow arrow), the uterus (green arrow), and the tumor nodule (white arrow). Scale bar = 2 mm.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Numerical data used for graphs in <xref ref-type="fig" rid="fig8">Figure 8</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91766-fig8-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91766-fig8-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this report, we investigated survival mechanisms in a model of HGSOC dormancy. We utilized a modified CRISPR screening approach that was adapted to discover gene loss events in largely non-proliferative conditions. We compared essential genes discovered in the screen with gene expression increases identified by RNA-seq in dormant HGSOC cultures. This implicated the Netrin signaling pathway in HGSOC spheroid survival. We independently validated the role of Netrins, their receptors, and downstream intracellular targets MEK and ERK in the survival biology of HGSOC cells in dormant culture and in vivo in xenografts. Furthermore, we reveal that overexpression of Netrin-1 and –3 are correlated with poor clinical outcome in HGSOC and over expression of these ligands induces elevated survival in dormant HGSOC culture conditions and increased disease spread in a xenograft model of dissemination. Our work implicates Netrins, their receptors, and MEK-ERK as a previously unappreciated, but critical signaling network in HGSOC survival.</p><p>HGSOC spheroid cell biology has presented a unique challenge to cancer chemotherapy. Dormant spheroids are most abundant in patients with late-stage disease and they contribute to therapeutic resistance and seed metastases (<xref ref-type="bibr" rid="bib1">Ahmed and Stenvers, 2013</xref>; <xref ref-type="bibr" rid="bib47">Narod, 2016</xref>; <xref ref-type="bibr" rid="bib32">Keyvani et al., 2019</xref>). Hence, there is a critical unmet need to understand HGSOC spheroid dependencies and target them therapeutically. Our data suggests that Netrin signaling is a universally active mechanism in spheroid cell survival. HGSOC is characterized by extensive genomic rearrangements and copy number variants (<xref ref-type="bibr" rid="bib48">Network CGA, 2011</xref>), and we speculate that Netrin signaling is retained because of the extensive redundancy of components of this pathway. Netrin-1 and –3 can both contribute to survival signaling and knock out of three or four different Netrin receptors is necessary to compromise Netrin signaling in survival. A key goal for the future is to identify Netrin-1 or –3 overexpression patients and compare their specific disease progression patterns with our xenograft model. This will be most informative of the effects of Netrin ligand overexpression in scenarios of dormancy, metastasis, and chemotherapy resistance.</p><p>This study demonstrates that Netrins function to stimulate UNC5H and fibronectin repeat containing receptors such as DCC to activate survival signals in HGSOC spheroids. This is distinct from the known role of UNC5H and DCC as dependence receptors where Netrin inhibits their pro-apoptotic signaling (<xref ref-type="bibr" rid="bib6">Brisset et al., 2021</xref>). Our data does not show elevated survival of spheroid cells in response to deletions of receptors, even in instances where families of Netrin receptors are co-deleted. Consistent with this observation, over expression of Netrin-1 or –3 in OVCAR8 cells stimulates higher level survival in suspension. In colon cancer, deletion of DCC confers a survival advantage and underscores the dependence receptor concept (<xref ref-type="bibr" rid="bib23">Fearon et al., 1990</xref>; <xref ref-type="bibr" rid="bib44">Mehlen et al., 1998</xref>). In HGSOC DCC or UNC5H deletions are relatively rare (<xref ref-type="bibr" rid="bib48">Network CGA, 2011</xref>). This suggests that ovarian cancer cells utilize Netrin signals for positive survival signaling instead of to neutralize inherent death signals from dependence receptors. Our data suggests that Netrin activates MEK and ERK to support cell survival indicating that targeting ligands, receptors or downstream at MEK are all possible approaches to inhibit this survival pathway. Netrin-1 inhibition in solid tumor xenograft models of melanoma have been shown to be effective in combination with chemotherapy (<xref ref-type="bibr" rid="bib4">Boussouar et al., 2020</xref>), but its effects on a dormant scenario are unknown. Identifying agents that cooperate with standard HGSOC chemotherapeutic agents such as carboplatin would offer an attractive strategy to eradicate dormant cells while combating progressive disease. Alternatively, a novel approach to targeting dormancy discovered in this study is, ironically, MEK inhibition. While MAPK signaling in cancer is universally known for its role in proliferation (<xref ref-type="bibr" rid="bib21">Downward, 2003</xref>), and MEK inhibitors are used to block proliferation (<xref ref-type="bibr" rid="bib3">Barbosa et al., 2021</xref>; <xref ref-type="bibr" rid="bib24">Flaherty et al., 2012</xref>), it is noteworthy that Netrin stimulation of MAPK signaling is reported to provide survival signals and to guide axon outgrowth in a non-proliferative context (<xref ref-type="bibr" rid="bib25">Forcet et al., 2002</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2017a</xref>). Dormancy is characterized by low phospho-ERK levels (<xref ref-type="bibr" rid="bib61">Sosa et al., 2014</xref>; <xref ref-type="bibr" rid="bib64">Yeh and Ramaswamy, 2015</xref>), indicating low MEK activity, however low levels of RAS-MAPK signaling are known to provide survival signals (<xref ref-type="bibr" rid="bib21">Downward, 2003</xref>). A challenge with deploying MEK inhibitors as an anti-dormancy setting in HGSOC therapy is its incompatibility with standard chemotherapies that rely on cell proliferation. Overall, our study aimed to identify potential new therapeutic targets in dormancy and Netrins and MEK are potential new candidates for dormant HGSOC disease.</p><p>Current literature offers little to connect Netrins with HGSOC beyond the observation that <italic>NTN1</italic> expression is increased in tumors compared to benign lesions (<xref ref-type="bibr" rid="bib50">Papanastasiou et al., 2011</xref>). Similarly, dormancy literature does not include a role for Netrins (<xref ref-type="bibr" rid="bib61">Sosa et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Phan and Croucher, 2020</xref>; <xref ref-type="bibr" rid="bib27">Goddard et al., 2018</xref>; <xref ref-type="bibr" rid="bib64">Yeh and Ramaswamy, 2015</xref>; <xref ref-type="bibr" rid="bib56">Recasens and Munoz, 2019</xref>). However, we expect that Netrin signaling may play an unappreciated role in dormancy in other cancer disease site paradigms. As stated in the introduction, dormancy is characterized by acquisition of stem like properties, EMT, and in most paradigms it involves rare cells establishing themselves in perivascular or bone marrow niches and Netrins have also been implicated in these processes (<xref ref-type="bibr" rid="bib57">Renders et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Ozmadenci et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Lengrand et al., 2023</xref>; <xref ref-type="bibr" rid="bib22">Ducarouge et al., 2023</xref>; <xref ref-type="bibr" rid="bib9">Cassier et al., 2023</xref>). Inhibition of Netrin-1 with NP137 and treatment with decitabine has been shown to reduce lung seeding suggesting that Netrins are relevant in a metastatic scenario that may include dormant intermediate steps in dissemination (<xref ref-type="bibr" rid="bib28">Grandin et al., 2016</xref>). Furthermore, Netrin signaling through UNC5B is known to direct vascular branching (<xref ref-type="bibr" rid="bib41">Lu et al., 2004</xref>). This suggests that Netrins are available in the perivascular niche where dormant cells often reside. Lastly, Netrin-1 has been shown to be a component of the bone marrow niche that suppresses hematopoietic stem cell proliferation (<xref ref-type="bibr" rid="bib57">Renders et al., 2021</xref>). While not a cancer dormancy scenario, it indicates that Netrins support some solitary dormant cell properties and are expressed by resident cells in the appropriate dormant cell niches beyond just HGSOC. For these reasons we expect Netrins will have a significant role in tumor dormancy beyond ovarian cancer.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Cell lines and engineering Cas9 +cells</title><p>High-grade serous ovarian cancer (HGSOC) cell lines OVCAR3, OVCAR4, OVCAR8, COV318, TOV1946, and iOvCa147 were used in this study. The iOvCa147 cells have previously been characterized and reported (<xref ref-type="bibr" rid="bib62">Tong et al., 2017</xref>). All cell lines were verified by STR analysis. iOvCa147, OVCAR8, and TOV1946 cells were engineered to express Cas9 using pLentiCas9-Blast and clones were isolated. High Cas9 editing efficiency was determined by viability studies using sgRNAs targeting selected fitness genes (PSMD1, PSMD2, EIF3D) and a non-targeting control (LacZ) as previously described (<xref ref-type="bibr" rid="bib29">Hart et al., 2015</xref>).</p></sec><sec id="s4-2"><title>Lentiviral sgRNA library preparation</title><p>HEK293T cells were transfected with the combined A and B components of the GeCKO v2 whole genome library (123,411 sgRNAs in total) along with plasmids encoding lentiviral packaging proteins (<xref ref-type="bibr" rid="bib58">Sanjana et al., 2014</xref>). Media was collected 2–3 days later, cells and debris were pelleted by centrifugation, and supernatant containing viral particles was filtered through a 0.45 µM filter and stored at −80 °C with 1.1 g/100 mL BSA.</p></sec><sec id="s4-3"><title>GO-CRISPR screens in iOvCa147, OVCAR8, and TOV1946 cells</title><p>Cas9-positive and Cas9-negative cells were separately transduced with lentiviruses at a multiplicity of infection of 0.3 and with a predicted library coverage of &gt;1000-fold. Cells were selected in puromycin and maintained in complete media (DMEM/F12 with 10% FBS, 1% pen-strep-glutamine), containing puromycin in all following steps. More than 10<sup>9</sup> cells were collected and split into three groups consisting of approximately 3.0×10<sup>8</sup> cells. Triplicate samples of 6.2×10<sup>7</sup> cells were saved for sgRNA sequence quantitation (T<sub>0</sub>). The remaining cells were seeded at 2.0×10<sup>6</sup> cells/mL in 20x10 cm ULA plates. Following 2 days of culture, media containing spheroids was transferred to 10x15 cm adherent tissue culture plates. The next day unattached spheroid cells were collected and re-plated onto additional 15 cm plates. This process was repeated for a total of 5 days to maximally capture viable cells. Attached cells were collected and pooled for DNA extraction (T<sub>f</sub>). Genomic DNA was extracted using the QIAmp DNA Blood Maxi Kit (Qiagen, #51194). PCR amplification and barcoding performed as described (Hart paper, Cell, 2015) using NEBNext Q5 Ultra mastermix (NEB, # MO544). PCR products were extracted from agarose using a Monarch DNA Gel Extraction Kit (NEB, # T1020), quantitated and next generation sequencing was performed using an Illumina NextSeq 75 cycle High Output kit on an Illumina NextSeq platform.</p></sec><sec id="s4-4"><title>TRACS analysis</title><p>The library reference file containing a list of all sgRNAs and their sequences (CSV file), raw reads for the pooled sgRNA library FASTQ files (L0) and raw reads (FASTQ files) for all T<sub>0</sub> and T<sub>f</sub> timepoints and replicates for Cas9-positive and Cas9-negative cells were loaded into TRACS (<ext-link ext-link-type="uri" xlink:href="https://github.com/developerpiru/TRACS">https://github.com/developerpiru/TRACS</ext-link>, copy archived at <xref ref-type="bibr" rid="bib17">developerpiru, 2020</xref>; <xref ref-type="bibr" rid="bib53">Perampalam et al., 2020</xref>). TRACS then automatically trimmed the reads using Cutadapt (v1.15), built a Bowtie2 (v2.3.4.1) index and aligned the reads using Samtools (v1.7). TRACS used the MAGeCK read count function (v0.5.6) to generate read counts and incremented all reads by 1 to prevent zero counts and division-by-zero errors. The TRACS algorithm was then run using this read count file to determine the Library Enrichment Score (ES), Initial ES, Final ES and the Enrichment Ratio (ER) for each gene. VisualizeTRACS was used to generate graphs of Initial and Final ratios.</p></sec><sec id="s4-5"><title>Pathway enrichment analyses</title><p>For GO-CRISPR screens and multi-omics comparisons, we used the filtered list of genes obtained using TRACS and performed gene ontology and pathway enrichment analysis using the ConsensusPathDB enrichment analysis test (Release 34 (15.01.2019), <ext-link ext-link-type="uri" xlink:href="http://cpdb.molgen.mpg.de/">http://cpdb.molgen.mpg.de/</ext-link>) for top-ranked genes of interest. p<sub>adj</sub> values and ER values for each gene were used as inputs. The minimum required genes for enrichment was set to 45 and the FDR-corrected p<sub>adj</sub> value cutoff was set to &lt;0.01. The Reactome pathway dataset was used as the reference. For each identified pathway, ConsensusPathDB provides the number of enriched genes and a q value (p<sub>adj</sub>) for the enrichment. Bar plots were generated in R 3.6.2 using these values to depict the significant pathways identified.</p></sec><sec id="s4-6"><title>Generating DYRK1A knockout cells</title><p>A double cutting CRISPR/Cas9 approach with a pair of sgRNAs (sgRNA A and B) was used to completely excise exon 2 (322 bp region) of <italic>DYRK1A</italic> using a px458 vector (Addgene #48138) that was modified to express the full CMV promoter. PCR primers that flank the targeted region of <italic>DYRK1A</italic> were used to verify deletion. Single-cell clones were generated by liming dilutions and evaluated for DYRK1A status by PCR, western blot, and sequencing. See Key resource table for sgRNA and PCR primer sequences.</p></sec><sec id="s4-7"><title>DYRK1A IP kinase assay</title><p>Whole cell lysates from adherent parental iOvCa147 cells and <italic>DYRK1A<sup>-/-</sup></italic> cells were extracted using complete RIPA buffer and incubated overnight with DYRK1A antibody (Cell Signaling Technology anti-DYRK1A rabbit antibody #8765). Samples were then washed with buffer and Dynabeads (Thermo Fisher Scientific Dynabeads Protein G #10003D) were added for 2 hr. Samples were then washed with buffer and recombinant Tau protein (Sigma recombinant Tau protein #T0576) and ATP (Sigma #A1852) were added and samples were incubated for 30 min at 37 °C. 5 x SDS was then added and samples were resolved by SDS-PAGE. Antibodies used for western blotting were phosphospecific Tau antibody (Cell Signaling Technology phospho-Tau Ser-404 rabbit antibody #20194) and Tau protein (Cell Signaling Technology anti-Tau rabbit antibody #46687).</p></sec><sec id="s4-8"><title>RNA preparation and RNA-sequencing</title><p>Total RNA was collected from parental iOvCa147 cells and <italic>DYRK1A<sup>-/-</sup></italic> cells from 24 hr adherent or 6 hr spheroid conditions using the Monarch Total RNA Miniprep Kit (NEB #T2010S) as described above. RNA was collected in three replicates for each condition (adherent and spheroids). Samples were quantitated using Qubit 2.0 Fluorometer (Thermo Fisher Scientific) and quality control analysis using Agilent 2100 Bioanalyzer (Agilent Technologies #G2939BA) and RNA 6000 Nano Kit (Agilent Technologies #5067–1511). Ribosomal RNA removal and library preparation was performed using ScriptSeq Complete Gold Kit (Illumina #BEP1206). High-throughput sequencing was performed on an Illumina NextSeq 500 platform (mid-output, 150-cycle kit).</p></sec><sec id="s4-9"><title>RNA-seq analyses</title><p>Raw FASTQ data was downloaded from Illumina BaseSpace. Reads were aligned using STAR 2.6.1 a <xref ref-type="bibr" rid="bib20">Dobin et al., 2013</xref> to the human genome (Homo_sapiens.GRCh38.dna.primary_assembly.fa; sjdbGTFfile: Homo_sapiens.GRCh38.92.gtf) to generate read counts. DESeq2 was run with BEAVR (<xref ref-type="bibr" rid="bib52">Perampalam and Dick, 2020</xref>) and used to analyze read counts (settings: False discovery rate (FDR): 10%; drop genes with less than 1 reads) to identify differentially expressed genes (log<sub>2</sub> fold change &gt;1 for upregulated genes; or log<sub>2</sub> fold change &lt; –1 for downregulated genes; p<sub>adj</sub> &lt;0.05) for the following comparisons: parental iOvCa147 adherent cells vs. parental iOvCa147 spheroid cells; or parental iOvCa147 spheroid cells vs. <italic>DYRK1A<sup>-/-</sup></italic> spheroid cells. For RNA-seq, we formed pathway analyses in BEAVR and downloaded the pathway enrichment table to construct bar plots and determine overlapping pathways using R 3.6.2.</p></sec><sec id="s4-10"><title>Western blots</title><p>Adherent cells were washed in 1 x PBS and lysed on the plate by the addition of complete RIPA buffer with protease (Cell Signaling Technology #5871 S) and phosphatase (Cell Signaling Technologies #5870 S) inhibitors and incubated for 5–10 min on ice. Spheres were collected by gentle centrifugation at 300 rpm, washed gently in ice cold PBS, centrifuged again and then resuspended in RIPA buffer as above. Samples were then centrifuged at 14,000 RPM at 4 °C for 10 min. The supernatant liquid for each sample was collected and the pellets re-extracted with RIPA containing the above inhibitor cocktails. Following centrifugation, the supernatants for each treatment were collected and pooled. Protein was determined by Bradford assay. To assess the effect of Netrin 1 on downstream signaling, spheres incubated under non adherent conditions for 5 days were challenged with the addition of 500 ng/ml human recombinant Netrin-1 (R&amp;D Systems #6419-N1-025) for a period of 20 min before collection. Lysates were mixed with 5 x SDS loading dye buffer and resolved using standard SDS-PAGE protocols. Antibodies used for blotting were p42/44 MAPK (Erk1/2) (Cell Signaling Technology rabbit antibody #4695), Phospho-p44/42 MAPK(Erk1/2) T202/Y204 (Cell Signaling Technology; rabbit antibody #4370), p38 MAPK (Cell Signaling Technology; rabbit antibody #9212), p38 MAPK T180/Y182 (Cell Signaling Technology; rabbit antibody #9211), p130(RBL2, Santa Cruz Biotechnology, rabbit antibody sc-317 discontinued), Ki67 (Abcam rabbit antibody, # ab16667), DYRK1A (Cell Signaling Technology anti-DYRK1A rabbit antibody #8765), Netrin-1 (Abcam rabbit antibody #ab126729), Netrin-3 (Abcam rabbit antibody #ab185200), α-tubulin (Cell Signaling Technology anti-αTubulin rabbit antibody #2125) and β-actin (Millipore Sigma rabbit antibody #A2066).</p></sec><sec id="s4-11"><title>RT-qPCR analysis of gene expression</title><p>Cells from a minimum of three biological replicates were triturated off the plate using Versene (0.5 mM EDTA in PBS), collected, counted and 10<sup>6</sup> cells plated onto Ultra-Low Attachment cell culture dishes (Corning) to induce sphere formation. The spheres were collected after 24 hr and RNA extracted using the Monarch Total RNA Miniprep Kit (New England Biolabs #T2010S). RNA was extracted from adherent cells directly from the plate. Extracted RNA was quantitated using a NanoDrop and stored at –80<sup>o</sup> until used. First strand cDNA was generated from isolated RNA using the iScript cDNA Synthesis Kit (Bio-Rad, #1708890) and RT-qPCR performed on the resulting cDNA (diluted 5-fold) using the iQ SYBR Green Supermix (Bio-Rad, #1708882) and following the manufactures instructions. Reactions were performed in 0.2 ml non-skirted low profile 96 well PCR plates (Thermo Fisher Scientific, #AD-0700) using a CFX Connect Real Time System thermo-cycler (Bio-Rad).</p></sec><sec id="s4-12"><title>TCGA patient data analyses</title><p>We used the cBioPortal for Cancer Genomics (<ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org">https://www.cbioportal.org</ext-link>; <xref ref-type="bibr" rid="bib11">Cerami et al., 2012</xref>) to analyze Netrin pathway alterations in Ovarian Serous Cystadenocarcinoma patients (TCGA, PanCancer Atlas) for genomic alterations and mRNA expression. OncoPrints were generated for mRNA expression (mean z-score threshold ±1.5), and mutations and putative copy number alterations for the following genes: <italic>NTN1, NTN3, NTN4, NTN5, UNC5A, UNC5B, UNC5C, UNC5D, DCC, DSCAM</italic>. Survival analysis of <italic>NTN1,</italic> and <italic>–3</italic> utilized patients from TCGA, PanCancer Atlas dataset and RNA-seq expression (high expression z-score threshold &gt;1.2 and low is below 1.2).</p></sec><sec id="s4-13"><title>Generation of gene knockout cell lines</title><p>Gibson Assembly (NEB #E2611) was used to clone sgRNAs sequences derived from the GeCKO v2 library per gene of interest (<italic>NTN1, NTN3, NTN4, NTN5, DSCAM, DCC, NEO1, UNC5A, UNC5B, UNC5C, UNC5D,</italic> and <italic>EGFP</italic> control (see Key resource table for sgRNA sequences for each)) into lentiCRISPR v2 (Addgene #52961). For individual gene knockouts pooled libraries of up to four sgRNAs were generated. For multiple gene knockouts pooled libraries of two sgRNAs/gene were constructed. To each 20- nucleotide guide (see Key resource table) was appended the 5’ sequence, 5’-<named-content content-type="sequence">TATCTTGTGGAAAGGACGAAACACC</named-content>-3’ and the 3’ sequence, 5’-<named-content content-type="sequence">GTTTTAGAGCTAGAAATAGCAAGTTAAAAT</named-content>-3’ (<xref ref-type="bibr" rid="bib63">Wang et al., 2016</xref>). A 100 bp fragment was then generated using the forward primer, 5’-<named-content content-type="sequence">GGCTTTATATATCTTGTGGAAAGGACGAAACACCG</named-content>-3’, and reverse primer, 5’-<named-content content-type="sequence">CTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC</named-content>-3’. The resulting gel purified fragment was quantitated by Qubit and cloned into the lentiviral vector LentiCRISPR-V2 previously digested with BsmBI (New England Biolabs, # R0739) as described (<xref ref-type="bibr" rid="bib63">Wang et al., 2016</xref>). To generate virus particles, HEK293T cells were transfected with the assembled plasmid along with plasmids encoding lentiviral packaging proteins. Media was collected after 2–3 days and any cells or debris were pelleted by centrifugation at 500 x <italic>g</italic>. Supernatant containing viral particles was filtered through a low protein binding 0.45 µM filter. For each knockout, it was important to ensure that each target cell was transduced with a full complement of guides. To ensure this, the cells were transduced at relatively high MOI. Briefly, 25,000 cells were plated and transduced with fresh HEK293T conditioned media containing virus. While we did not titer the viral preparations for these experiments, previous experience indicated that we could generate sufficiently high virus titers using our protocol. Under these conditions, we found a lack of puromycin sensitive cells following 2–3 days in media containing 2–4 μg/ml puromycin indicating that every cell received at least one virus particle. Multi-gene knock outs were created through multiple rounds of infection with the relevant culture supernatants followed by one round of puromycin selection.</p></sec><sec id="s4-14"><title>Generation of gene overexpression cell lines</title><p>Plasmids encoding Netrin1 and Netrin3 were obtained from Addgene (Ntn1-Fc-His, #72104 and Ntn3-Fc-His, #72105). Netrin1 was PCR amplified using the forward primer 5’-<named-content content-type="sequence">GCTATCGATATCCCAAACGCCACCATGATGCGCGCTGTGTGGGAGGCGCTG</named-content>-3’ and reverse 5’-<named-content content-type="sequence">GCTATCTCTAGAGGCCTTCTTGCACTTGCCCTTCTTCTCCCG</named-content>-3’ and cloned into the EcoRV/XbaI sites of pcDNA3.1/myc-HisA. For lentiviral expression, NTN1 was PCR amplified from pcDNA NTN1 using the primers, forward 5’-<named-content content-type="sequence">CACTGTAGATCTCCAAACGCCACCATGATGCGCGCTGTGTGGGAGGCGCTG</named-content>-3’ and, reverse 5’-<named-content content-type="sequence">ACGCGTGAATTCTTATCAACCGGTATGCATATTCAGATCCTCTTCTGAGAT</named-content>-3’. Netrin 3 was amplified using the forward primer 5’-<named-content content-type="sequence">GCTAGCGCGGCCGCCACCATGCCTGGCTGGCCCTGG</named-content>-3’ and reverse primer 5’-<named-content content-type="sequence">CTGAGATCTAGAAGCAGCACTACAACGACCACGACGTTCACG</named-content>-3’and cloned into the NotI/XbaI sites of pcDNA3.1/myc-HisA. For lentiviral expression, NTN3 was amplified from pcDNA NTN3 using the forward primer 5’-<named-content content-type="sequence">CTCGAGAGATCTGCGGCCGCCACCATGCCTGGCTGGCCCTGG</named-content>-3’ and the same reverse primer as for NTN1. In this way both constructs carry a C-terminal Myc tag. Both cDNA’s were inserted into the BamHI/EcoRI sites of the lentiviral expression vector FUtdTW (Addgene #22478). Construction of lentiviral particle and transduction into the target cells was as described above.</p></sec><sec id="s4-15"><title>Spheroid formation and reattachment viability assays</title><p>For each targeted gene or cDNA expressed in iOvCa147, OVCAR3, OVCAR4, OVCAR8, COV318, or TOV1946 cells, spheroid viability was assayed as follows: Three to ten biological replicate cultures of knockout cells were cultured for 72 hours in suspension conditions using ULA plasticware (2×10<sup>6</sup> cells per well) to allow spheroid formation. Addition of therapeutics (Tramatinib, Selleckchem, #S4484) was made at the time of plating. Spheroids were collected and transferred directly to standard plasticware to facilitate reattachment for 24 hr, or dissociated and mixed with trypan blue. Reattached cells were fixed in 25% methanol in PBS for 3 min. Fixed cells were incubated for 30 min with shaking in 0.5% crystal violet, 25% methanol in PBS. Plates were carefully immersed in water to remove residual crystal violet and destained in 10% acetic acid in 1 x PBS for 1 hr with shaking to extract crystal violet from cells. Absorbance of crystal violet was measured at 590 nm using a microplate reader (Perkin Elmer Wallac 1420).</p></sec><sec id="s4-16"><title>Xenografts</title><p>ARRIVE principles were followed in carrying out xenograft experiments. Female NOD-SCID mice were purchased from JAX (#001303). They were randomly selected prior to being engrafted between six and eight weeks of age with 4x10<sup>6</sup> OVCAR8 control or modified derivatives. Five to 10 mice were housed for 14 days, 35 days, or until humane endpoint for each OVCAR8 or modified derivative. Following euthanasia all mice were subjected to a necropsy to analyze disease spread. Tumor lesions were photographed and quantitated by individuals unaware of the genotypes. Abdominal organs and associated tumor lesions were fixed in 10% formalin overnight and transferred to 70% ethanol and later embedded, sectioned and stained as described below.</p></sec><sec id="s4-17"><title>Patient derived spheroids</title><p>Patient derived spheroids were isolated from ascites fluid obtained from debulking surgical procedures. These HGSOC samples were obtained with permission and institutional research ethics oversight (Project ID #115904). Spheroids were prepared by filtering the ascites fluid through a 100 μm mesh filter and washing the captured spheroids from the filter with PBS. The spheres were collected by gravity on ice in PBS, washed twice with ice cold PBS and allowed to settle on ice. Spheres were then fixed for 20 min in 10% formalin, washed, and resuspended in PBS before being embedded in paraffin.</p></sec><sec id="s4-18"><title>Histology and immunohistochemistry</title><p>Fixed organs from xenografts or spheroids were embedded in paraffin, sectioned, and stained with H&amp;E using standard methods. For immunohistochemistry, sections were deparaffinized by standard procedures and antigen retrieval was performed in 10 mM citrate, pH6.0. The sections were blocked with 10% goat serum/3% BSA/0.3% Triton X-100 and stained with antibodies to Netrin-1 (Abcam #ab126729, 1:200), Cytokeratin (human specific cytokeratin 7 and 8, ZETA Corporation #Z2018ML, 1:200), EpCAM (Cell Signaling Technology, #14452, 1:250), p53 (Cell Signaling Technologies, #2527, 1:125), Netrin-3 (1:250), Ki67 (Cell Signaling Technology, #12202, 1:400) and p130 (RBL2, Santa Cruz Biotechnology, SC-317, 1:150). Netrin-3 antibodies were generated using immunized rabbits and their generation and purification will be published elsewhere. Primary antibodies were followed with a biotinylated anti-rabbit (Vector Labs, # BA-1000) or anti-mouse (Jackson ImmunoResearch, #115-067-003) IgG as a secondary antibody (1:500). Proteins were visualized using DAB chemistry (ImmPACT DAB, Vector Labs, #SK-4105).</p></sec><sec id="s4-19"><title>Statistical analyses</title><p>Specific statistical tests used are indicated in the figure legends for each experiment. Analysis was done using GraphPad Prism 6.</p></sec><sec id="s4-20"><title>Materials availability</title><p>All previously unpublished reagents created in this study are available on request from the corresponding author.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Founder of Netris Pharma</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con6"><p>Resources, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con8"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con9"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Methodology</p></fn><fn fn-type="con" id="con11"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Visualization, Methodology</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This work was carried out in accordance with standards set by the Canadian Council on Animal Care. Animal experiments were overseen by the Western University Animal Use Committee protocol 2020-039.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-91766-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All sequencing data have been deposited in GEO under accession codes GSE190294 and GSE150246. Source data for graphs and original blots are available in source data files, or from public databases as described in the methods section.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Perampalam</surname><given-names>P</given-names></name><name><surname>McDonald</surname><given-names>JI</given-names></name><name><surname>Passos</surname><given-names>DT</given-names></name><name><surname>Dick</surname><given-names>FA</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Netrin and its dependence receptors are mediators of high-grade serous ovarian cancer cell survival</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE190294">GSE190294</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Perampalam</surname><given-names>P</given-names></name><name><surname>McDonald</surname><given-names>JI</given-names></name><name><surname>Dick</surname><given-names>FA</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>GO-CRISPR: a highly controlled workflow to improve discovery of gene essentiality</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150246">GSE150246</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>N</given-names></name><name><surname>Stenvers</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research</article-title><source>Frontiers in Oncology</source><volume>3</volume><elocation-id>256</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2013.00256</pub-id><pub-id pub-id-type="pmid">24093089</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arakawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Netrin-1 and its receptors in tumorigenesis</article-title><source>Nature Reviews. Cancer</source><volume>4</volume><fpage>978</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1038/nrc1504</pub-id><pub-id pub-id-type="pmid">15573119</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbosa</surname><given-names>R</given-names></name><name><surname>Acevedo</surname><given-names>LA</given-names></name><name><surname>Marmorstein</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The MEK/ERK network as a therapeutic target in human cancer</article-title><source>Molecular Cancer Research</source><volume>19</volume><fpage>361</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-20-0687</pub-id><pub-id pub-id-type="pmid">33139506</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boussouar</surname><given-names>A</given-names></name><name><surname>Tortereau</surname><given-names>A</given-names></name><name><surname>Manceau</surname><given-names>A</given-names></name><name><surname>Paradisi</surname><given-names>A</given-names></name><name><surname>Gadot</surname><given-names>N</given-names></name><name><surname>Vial</surname><given-names>J</given-names></name><name><surname>Neves</surname><given-names>D</given-names></name><name><surname>Larue</surname><given-names>L</given-names></name><name><surname>Battistella</surname><given-names>M</given-names></name><name><surname>Leboeuf</surname><given-names>C</given-names></name><name><surname>Lebbé</surname><given-names>C</given-names></name><name><surname>Janin</surname><given-names>A</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Netrin-1 and its receptor dcc are causally implicated in melanoma progression</article-title><source>Cancer Research</source><volume>80</volume><fpage>747</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-1590</pub-id><pub-id pub-id-type="pmid">31806640</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowtell</surname><given-names>DD</given-names></name><name><surname>Böhm</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>AA</given-names></name><name><surname>Aspuria</surname><given-names>PJ</given-names></name><name><surname>Bast</surname><given-names>RC</given-names></name><name><surname>Beral</surname><given-names>V</given-names></name><name><surname>Berek</surname><given-names>JS</given-names></name><name><surname>Birrer</surname><given-names>MJ</given-names></name><name><surname>Blagden</surname><given-names>S</given-names></name><name><surname>Bookman</surname><given-names>MA</given-names></name><name><surname>Brenton</surname><given-names>JD</given-names></name><name><surname>Chiappinelli</surname><given-names>KB</given-names></name><name><surname>Martins</surname><given-names>FC</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Edmondson</surname><given-names>R</given-names></name><name><surname>Fotopoulou</surname><given-names>C</given-names></name><name><surname>Gabra</surname><given-names>H</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Gourley</surname><given-names>C</given-names></name><name><surname>Heong</surname><given-names>V</given-names></name><name><surname>Huntsman</surname><given-names>DG</given-names></name><name><surname>Iwanicki</surname><given-names>M</given-names></name><name><surname>Karlan</surname><given-names>BY</given-names></name><name><surname>Kaye</surname><given-names>A</given-names></name><name><surname>Lengyel</surname><given-names>E</given-names></name><name><surname>Levine</surname><given-names>DA</given-names></name><name><surname>Lu</surname><given-names>KH</given-names></name><name><surname>McNeish</surname><given-names>IA</given-names></name><name><surname>Menon</surname><given-names>U</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Nelson</surname><given-names>BH</given-names></name><name><surname>Nephew</surname><given-names>KP</given-names></name><name><surname>Pharoah</surname><given-names>P</given-names></name><name><surname>Powell</surname><given-names>DJ</given-names></name><name><surname>Ramos</surname><given-names>P</given-names></name><name><surname>Romero</surname><given-names>IL</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><name><surname>Stronach</surname><given-names>EA</given-names></name><name><surname>Balkwill</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer</article-title><source>Nature Reviews. Cancer</source><volume>15</volume><fpage>668</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1038/nrc4019</pub-id><pub-id pub-id-type="pmid">26493647</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brisset</surname><given-names>M</given-names></name><name><surname>Grandin</surname><given-names>M</given-names></name><name><surname>Bernet</surname><given-names>A</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Hollande</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dependence receptors: new targets for cancer therapy</article-title><source>EMBO Molecular Medicine</source><volume>13</volume><elocation-id>e14495</elocation-id><pub-id pub-id-type="doi">10.15252/emmm.202114495</pub-id><pub-id pub-id-type="pmid">34542930</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruikman</surname><given-names>CS</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Kemper</surname><given-names>AM</given-names></name><name><surname>van Gils</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Netrin family: role for protein isoforms in cancer</article-title><source>Journal of Nucleic Acids</source><volume>2019</volume><elocation-id>3947123</elocation-id><pub-id pub-id-type="doi">10.1155/2019/3947123</pub-id><pub-id pub-id-type="pmid">30923634</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buensuceso</surname><given-names>A</given-names></name><name><surname>Ramos-Valdes</surname><given-names>Y</given-names></name><name><surname>DiMattia</surname><given-names>GE</given-names></name><name><surname>Shepherd</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>AMPK-independent lkb1 activity is required for efficient epithelial ovarian cancer metastasis</article-title><source>Molecular Cancer Research</source><volume>18</volume><fpage>488</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-19-0530</pub-id><pub-id pub-id-type="pmid">31744879</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassier</surname><given-names>PA</given-names></name><name><surname>Navaridas</surname><given-names>R</given-names></name><name><surname>Bellina</surname><given-names>M</given-names></name><name><surname>Rama</surname><given-names>N</given-names></name><name><surname>Ducarouge</surname><given-names>B</given-names></name><name><surname>Hernandez-Vargas</surname><given-names>H</given-names></name><name><surname>Delord</surname><given-names>JP</given-names></name><name><surname>Lengrand</surname><given-names>J</given-names></name><name><surname>Paradisi</surname><given-names>A</given-names></name><name><surname>Fattet</surname><given-names>L</given-names></name><name><surname>Garin</surname><given-names>G</given-names></name><name><surname>Gheit</surname><given-names>H</given-names></name><name><surname>Dalban</surname><given-names>C</given-names></name><name><surname>Pastushenko</surname><given-names>I</given-names></name><name><surname>Neves</surname><given-names>D</given-names></name><name><surname>Jelin</surname><given-names>R</given-names></name><name><surname>Gadot</surname><given-names>N</given-names></name><name><surname>Braissand</surname><given-names>N</given-names></name><name><surname>Léon</surname><given-names>S</given-names></name><name><surname>Degletagne</surname><given-names>C</given-names></name><name><surname>Matias-Guiu</surname><given-names>X</given-names></name><name><surname>Devouassoux-Shisheboran</surname><given-names>M</given-names></name><name><surname>Mery-Lamarche</surname><given-names>E</given-names></name><name><surname>Allard</surname><given-names>J</given-names></name><name><surname>Zindy</surname><given-names>E</given-names></name><name><surname>Decaestecker</surname><given-names>C</given-names></name><name><surname>Salmon</surname><given-names>I</given-names></name><name><surname>Perol</surname><given-names>D</given-names></name><name><surname>Dolcet</surname><given-names>X</given-names></name><name><surname>Ray-Coquard</surname><given-names>I</given-names></name><name><surname>Blanpain</surname><given-names>C</given-names></name><name><surname>Bernet</surname><given-names>A</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer</article-title><source>Nature</source><volume>620</volume><fpage>409</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06367-z</pub-id><pub-id pub-id-type="pmid">37532934</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castets</surname><given-names>M</given-names></name><name><surname>Coissieux</surname><given-names>MM</given-names></name><name><surname>Delloye-Bourgeois</surname><given-names>C</given-names></name><name><surname>Bernard</surname><given-names>L</given-names></name><name><surname>Delcros</surname><given-names>JG</given-names></name><name><surname>Bernet</surname><given-names>A</given-names></name><name><surname>Laudet</surname><given-names>V</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inhibition of endothelial cell apoptosis by netrin-1 during angiogenesis</article-title><source>Developmental Cell</source><volume>16</volume><fpage>614</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2009.02.006</pub-id><pub-id pub-id-type="pmid">19386270</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Netrin-1 prevents rat primary cortical neurons from apoptosis via the dcc/erk pathway</article-title><source>Frontiers in Cellular Neuroscience</source><volume>11</volume><elocation-id>387</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2017.00387</pub-id><pub-id pub-id-type="pmid">29321724</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MW</given-names></name><name><surname>Yang</surname><given-names>ST</given-names></name><name><surname>Chien</surname><given-names>MH</given-names></name><name><surname>Hua</surname><given-names>KT</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Hsiao</surname><given-names>SM</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Hsiao</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>JL</given-names></name><name><surname>Wei</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>The stat3-mirna-92-wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer</article-title><source>Cancer Research</source><volume>77</volume><fpage>1955</fpage><lpage>1967</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1115</pub-id><pub-id pub-id-type="pmid">28209618</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>RJM</given-names></name><name><surname>Peart</surname><given-names>T</given-names></name><name><surname>Valdes</surname><given-names>YR</given-names></name><name><surname>DiMattia</surname><given-names>GE</given-names></name><name><surname>Shepherd</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids</article-title><source>Carcinogenesis</source><volume>33</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgr241</pub-id><pub-id pub-id-type="pmid">22045027</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>RJM</given-names></name><name><surname>Valdes</surname><given-names>YR</given-names></name><name><surname>Peart</surname><given-names>TM</given-names></name><name><surname>Fazio</surname><given-names>EN</given-names></name><name><surname>Bertrand</surname><given-names>M</given-names></name><name><surname>McGee</surname><given-names>J</given-names></name><name><surname>Préfontaine</surname><given-names>M</given-names></name><name><surname>Sugimoto</surname><given-names>A</given-names></name><name><surname>DiMattia</surname><given-names>GE</given-names></name><name><surname>Shepherd</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability</article-title><source>Carcinogenesis</source><volume>35</volume><fpage>1951</fpage><lpage>1961</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgu049</pub-id><pub-id pub-id-type="pmid">24562574</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>RJM</given-names></name><name><surname>Valdes</surname><given-names>YR</given-names></name><name><surname>Shepherd</surname><given-names>TG</given-names></name><name><surname>DiMattia</surname><given-names>GE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro</article-title><source>Journal of Ovarian Research</source><volume>8</volume><elocation-id>52</elocation-id><pub-id pub-id-type="doi">10.1186/s13048-015-0182-y</pub-id><pub-id pub-id-type="pmid">26239434</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="software"><person-group person-group-type="author"><collab>developerpiru</collab></person-group><year iso-8601-date="2020">2020</year><data-title>Tracs</data-title><version designator="swh:1:rev:fa8eb708f9deb48114f7aa7b8c7531e0b3e6093d">swh:1:rev:fa8eb708f9deb48114f7aa7b8c7531e0b3e6093d</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:4334dd5fbe75d9bb37ebcca61c5dce62acf01aed;origin=https://github.com/developerpiru/TRACS;visit=swh:1:snp:c5587180771d1353b0825c59e982284a957ad2c9;anchor=swh:1:rev:fa8eb708f9deb48114f7aa7b8c7531e0b3e6093d">https://archive.softwareheritage.org/swh:1:dir:4334dd5fbe75d9bb37ebcca61c5dce62acf01aed;origin=https://github.com/developerpiru/TRACS;visit=swh:1:snp:c5587180771d1353b0825c59e982284a957ad2c9;anchor=swh:1:rev:fa8eb708f9deb48114f7aa7b8c7531e0b3e6093d</ext-link></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz Osterman</surname><given-names>CJ</given-names></name><name><surname>Ozmadenci</surname><given-names>D</given-names></name><name><surname>Kleinschmidt</surname><given-names>EG</given-names></name><name><surname>Taylor</surname><given-names>KN</given-names></name><name><surname>Barrie</surname><given-names>AM</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Bean</surname><given-names>LM</given-names></name><name><surname>Sulzmaier</surname><given-names>FJ</given-names></name><name><surname>Jean</surname><given-names>C</given-names></name><name><surname>Tancioni</surname><given-names>I</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Uryu</surname><given-names>S</given-names></name><name><surname>Cordasco</surname><given-names>EA</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>XL</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Ojalill</surname><given-names>M</given-names></name><name><surname>Rappu</surname><given-names>P</given-names></name><name><surname>Heino</surname><given-names>J</given-names></name><name><surname>Mark</surname><given-names>AM</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Fisch</surname><given-names>KM</given-names></name><name><surname>Kolev</surname><given-names>VN</given-names></name><name><surname>Weaver</surname><given-names>DT</given-names></name><name><surname>Pachter</surname><given-names>JA</given-names></name><name><surname>Győrffy</surname><given-names>B</given-names></name><name><surname>McHale</surname><given-names>MT</given-names></name><name><surname>Connolly</surname><given-names>DC</given-names></name><name><surname>Molinolo</surname><given-names>A</given-names></name><name><surname>Stupack</surname><given-names>DG</given-names></name><name><surname>Schlaepfer</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy</article-title><source>eLife</source><volume>8</volume><elocation-id>e47327</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.47327</pub-id><pub-id pub-id-type="pmid">31478830</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Vona</surname><given-names>C</given-names></name><name><surname>Bezdan</surname><given-names>D</given-names></name><name><surname>Islam</surname><given-names>A</given-names></name><name><surname>Salichs</surname><given-names>E</given-names></name><name><surname>López-Bigas</surname><given-names>N</given-names></name><name><surname>Ossowski</surname><given-names>S</given-names></name><name><surname>de la Luna</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA polymerase II CTD kinase</article-title><source>Molecular Cell</source><volume>57</volume><fpage>506</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.12.026</pub-id><pub-id pub-id-type="pmid">25620562</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downward</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Targeting RAS signalling pathways in cancer therapy</article-title><source>Nature Reviews. Cancer</source><volume>3</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/nrc969</pub-id><pub-id pub-id-type="pmid">12509763</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ducarouge</surname><given-names>B</given-names></name><name><surname>Redavid</surname><given-names>AR</given-names></name><name><surname>Victoor</surname><given-names>C</given-names></name><name><surname>Chira</surname><given-names>R</given-names></name><name><surname>Fonseca</surname><given-names>A</given-names></name><name><surname>Hervieu</surname><given-names>M</given-names></name><name><surname>Bergé</surname><given-names>R</given-names></name><name><surname>Lengrand</surname><given-names>J</given-names></name><name><surname>Vieugué</surname><given-names>P</given-names></name><name><surname>Neves</surname><given-names>D</given-names></name><name><surname>Goddard</surname><given-names>I</given-names></name><name><surname>Richaud</surname><given-names>M</given-names></name><name><surname>Laval</surname><given-names>PA</given-names></name><name><surname>Rama</surname><given-names>N</given-names></name><name><surname>Goldschneider</surname><given-names>D</given-names></name><name><surname>Paradisi</surname><given-names>A</given-names></name><name><surname>Gourdin</surname><given-names>N</given-names></name><name><surname>Chabaud</surname><given-names>S</given-names></name><name><surname>Treilleux</surname><given-names>I</given-names></name><name><surname>Gadot</surname><given-names>N</given-names></name><name><surname>Ray-Coquard</surname><given-names>I</given-names></name><name><surname>Depil</surname><given-names>S</given-names></name><name><surname>Decaudin</surname><given-names>D</given-names></name><name><surname>Némati</surname><given-names>F</given-names></name><name><surname>Marangoni</surname><given-names>E</given-names></name><name><surname>Mery-Lamarche</surname><given-names>E</given-names></name><name><surname>Génestie</surname><given-names>C</given-names></name><name><surname>Tabone-Eglinger</surname><given-names>S</given-names></name><name><surname>Devouassoux-Shisheboran</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>KJ</given-names></name><name><surname>Gibert</surname><given-names>B</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Bernet</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Netrin-1 blockade inhibits tumor associated myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor</article-title><source>Cell Death and Differentiation</source><volume>30</volume><fpage>2201</fpage><lpage>2212</lpage><pub-id pub-id-type="doi">10.1038/s41418-023-01209-x</pub-id><pub-id pub-id-type="pmid">37633969</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Cho</surname><given-names>KR</given-names></name><name><surname>Nigro</surname><given-names>JM</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name><name><surname>Simons</surname><given-names>JW</given-names></name><name><surname>Ruppert</surname><given-names>JM</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Preisinger</surname><given-names>AC</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Identification of a chromosome 18q gene that is altered in colorectal cancers</article-title><source>Science</source><volume>247</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1126/science.2294591</pub-id><pub-id pub-id-type="pmid">2294591</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Infante</surname><given-names>JR</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Kefford</surname><given-names>RF</given-names></name><name><surname>Sosman</surname><given-names>J</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Schuchter</surname><given-names>L</given-names></name><name><surname>Cebon</surname><given-names>J</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Kudchadkar</surname><given-names>R</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>Falchook</surname><given-names>G</given-names></name><name><surname>Algazi</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Lebowitz</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Little</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Allred</surname><given-names>A</given-names></name><name><surname>Ouellet</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</article-title><source>The New England Journal of Medicine</source><volume>367</volume><fpage>1694</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1210093</pub-id><pub-id pub-id-type="pmid">23020132</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forcet</surname><given-names>C</given-names></name><name><surname>Stein</surname><given-names>E</given-names></name><name><surname>Pays</surname><given-names>L</given-names></name><name><surname>Corset</surname><given-names>V</given-names></name><name><surname>Llambi</surname><given-names>F</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MAPK activation</article-title><source>Nature</source><volume>417</volume><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/nature748</pub-id><pub-id pub-id-type="pmid">11986622</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giancotti</surname><given-names>FG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanisms governing metastatic dormancy and reactivation</article-title><source>Cell</source><volume>155</volume><fpage>750</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.10.029</pub-id><pub-id pub-id-type="pmid">24209616</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goddard</surname><given-names>ET</given-names></name><name><surname>Bozic</surname><given-names>I</given-names></name><name><surname>Riddell</surname><given-names>SR</given-names></name><name><surname>Ghajar</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dormant tumour cells, their niches and the influence of immunity</article-title><source>Nature Cell Biology</source><volume>20</volume><fpage>1240</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0214-0</pub-id><pub-id pub-id-type="pmid">30361702</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandin</surname><given-names>M</given-names></name><name><surname>Meier</surname><given-names>M</given-names></name><name><surname>Delcros</surname><given-names>JG</given-names></name><name><surname>Nikodemus</surname><given-names>D</given-names></name><name><surname>Reuten</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>TR</given-names></name><name><surname>Goldschneider</surname><given-names>D</given-names></name><name><surname>Orriss</surname><given-names>G</given-names></name><name><surname>Krahn</surname><given-names>N</given-names></name><name><surname>Boussouar</surname><given-names>A</given-names></name><name><surname>Abes</surname><given-names>R</given-names></name><name><surname>Dean</surname><given-names>Y</given-names></name><name><surname>Neves</surname><given-names>D</given-names></name><name><surname>Bernet</surname><given-names>A</given-names></name><name><surname>Depil</surname><given-names>S</given-names></name><name><surname>Schneiders</surname><given-names>F</given-names></name><name><surname>Poole</surname><given-names>K</given-names></name><name><surname>Dante</surname><given-names>R</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Stetefeld</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structural decoding of the netrin-1/UNC5 Interaction and its therapeutical implications in cancers</article-title><source>Cancer Cell</source><volume>29</volume><fpage>173</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.01.001</pub-id><pub-id pub-id-type="pmid">26859457</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>T</given-names></name><name><surname>Chandrashekhar</surname><given-names>M</given-names></name><name><surname>Aregger</surname><given-names>M</given-names></name><name><surname>Steinhart</surname><given-names>Z</given-names></name><name><surname>Brown</surname><given-names>KR</given-names></name><name><surname>MacLeod</surname><given-names>G</given-names></name><name><surname>Mis</surname><given-names>M</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Fradet-Turcotte</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Mero</surname><given-names>P</given-names></name><name><surname>Dirks</surname><given-names>P</given-names></name><name><surname>Sidhu</surname><given-names>S</given-names></name><name><surname>Roth</surname><given-names>FP</given-names></name><name><surname>Rissland</surname><given-names>OS</given-names></name><name><surname>Durocher</surname><given-names>D</given-names></name><name><surname>Angers</surname><given-names>S</given-names></name><name><surname>Moffat</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>High-resolution crispr screens reveal fitness genes and genotype-specific cancer liabilities</article-title><source>Cell</source><volume>163</volume><fpage>1515</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.11.015</pub-id><pub-id pub-id-type="pmid">26627737</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Nakhla</surname><given-names>H</given-names></name><name><surname>Friedman</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/RB2</article-title><source>International Journal of Cancer</source><volume>129</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1002/ijc.25692</pub-id><pub-id pub-id-type="pmid">20857490</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Richaud</surname><given-names>M</given-names></name><name><surname>Vieugué</surname><given-names>P</given-names></name><name><surname>Rama</surname><given-names>N</given-names></name><name><surname>Delcros</surname><given-names>JG</given-names></name><name><surname>Siouda</surname><given-names>M</given-names></name><name><surname>Sanada</surname><given-names>M</given-names></name><name><surname>Redavid</surname><given-names>AR</given-names></name><name><surname>Ducarouge</surname><given-names>B</given-names></name><name><surname>Hervieu</surname><given-names>M</given-names></name><name><surname>Breusa</surname><given-names>S</given-names></name><name><surname>Manceau</surname><given-names>A</given-names></name><name><surname>Gattolliat</surname><given-names>CH</given-names></name><name><surname>Gadot</surname><given-names>N</given-names></name><name><surname>Combaret</surname><given-names>V</given-names></name><name><surname>Neves</surname><given-names>D</given-names></name><name><surname>Ortiz-Cuaran</surname><given-names>S</given-names></name><name><surname>Saintigny</surname><given-names>P</given-names></name><name><surname>Meurette</surname><given-names>O</given-names></name><name><surname>Walter</surname><given-names>T</given-names></name><name><surname>Janoueix-Lerosey</surname><given-names>I</given-names></name><name><surname>Hofman</surname><given-names>P</given-names></name><name><surname>Mulligan</surname><given-names>P</given-names></name><name><surname>Goldshneider</surname><given-names>D</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Gibert</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting netrin-3 in small cell lung cancer and neuroblastoma</article-title><source>EMBO Molecular Medicine</source><volume>13</volume><elocation-id>e12878</elocation-id><pub-id pub-id-type="doi">10.15252/emmm.202012878</pub-id><pub-id pub-id-type="pmid">33719214</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keyvani</surname><given-names>V</given-names></name><name><surname>Farshchian</surname><given-names>M</given-names></name><name><surname>Esmaeili</surname><given-names>SA</given-names></name><name><surname>Yari</surname><given-names>H</given-names></name><name><surname>Moghbeli</surname><given-names>M</given-names></name><name><surname>Nezhad</surname><given-names>SRK</given-names></name><name><surname>Abbaszadegan</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ovarian cancer stem cells and targeted therapy</article-title><source>Journal of Ovarian Research</source><volume>12</volume><elocation-id>120</elocation-id><pub-id pub-id-type="doi">10.1186/s13048-019-0588-z</pub-id><pub-id pub-id-type="pmid">31810474</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kryza</surname><given-names>D</given-names></name><name><surname>Wischhusen</surname><given-names>J</given-names></name><name><surname>Richaud</surname><given-names>M</given-names></name><name><surname>Hervieu</surname><given-names>M</given-names></name><name><surname>Sidi Boumedine</surname><given-names>J</given-names></name><name><surname>Delcros</surname><given-names>JG</given-names></name><name><surname>Besse</surname><given-names>S</given-names></name><name><surname>Baudier</surname><given-names>T</given-names></name><name><surname>Laval</surname><given-names>PA</given-names></name><name><surname>Breusa</surname><given-names>S</given-names></name><name><surname>Boutault</surname><given-names>E</given-names></name><name><surname>Clermidy</surname><given-names>H</given-names></name><name><surname>Rama</surname><given-names>N</given-names></name><name><surname>Ducarouge</surname><given-names>B</given-names></name><name><surname>Devouassoux-Shisheboran</surname><given-names>M</given-names></name><name><surname>Chezal</surname><given-names>JM</given-names></name><name><surname>Giraudet</surname><given-names>AL</given-names></name><name><surname>Walter</surname><given-names>T</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Sarrut</surname><given-names>D</given-names></name><name><surname>Gibert</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors</article-title><source>EMBO Molecular Medicine</source><volume>15</volume><elocation-id>e16732</elocation-id><pub-id pub-id-type="doi">10.15252/emmm.202216732</pub-id><pub-id pub-id-type="pmid">36876343</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larrieu-Lahargue</surname><given-names>F</given-names></name><name><surname>Welm</surname><given-names>AL</given-names></name><name><surname>Thomas</surname><given-names>KR</given-names></name><name><surname>Li</surname><given-names>DY</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Netrin-4 induces lymphangiogenesis in vivo</article-title><source>Blood</source><volume>115</volume><fpage>5418</fpage><lpage>5426</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-11-252338</pub-id><pub-id pub-id-type="pmid">20407033</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengrand</surname><given-names>J</given-names></name><name><surname>Pastushenko</surname><given-names>I</given-names></name><name><surname>Vanuytven</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Venet</surname><given-names>D</given-names></name><name><surname>Sarate</surname><given-names>RM</given-names></name><name><surname>Bellina</surname><given-names>M</given-names></name><name><surname>Moers</surname><given-names>V</given-names></name><name><surname>Boinet</surname><given-names>A</given-names></name><name><surname>Sifrim</surname><given-names>A</given-names></name><name><surname>Rama</surname><given-names>N</given-names></name><name><surname>Ducarouge</surname><given-names>B</given-names></name><name><surname>Van Herck</surname><given-names>J</given-names></name><name><surname>Dubois</surname><given-names>C</given-names></name><name><surname>Scozzaro</surname><given-names>S</given-names></name><name><surname>Lemaire</surname><given-names>S</given-names></name><name><surname>Gieskes</surname><given-names>S</given-names></name><name><surname>Bonni</surname><given-names>S</given-names></name><name><surname>Collin</surname><given-names>A</given-names></name><name><surname>Braissand</surname><given-names>N</given-names></name><name><surname>Allard</surname><given-names>J</given-names></name><name><surname>Zindy</surname><given-names>E</given-names></name><name><surname>Decaestecker</surname><given-names>C</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Salmon</surname><given-names>I</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Voet</surname><given-names>T</given-names></name><name><surname>Bernet</surname><given-names>A</given-names></name><name><surname>Blanpain</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Pharmacological targeting of netrin-1 inhibits EMT in cancer</article-title><source>Nature</source><volume>620</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06372-2</pub-id><pub-id pub-id-type="pmid">37532929</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengyel</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ovarian cancer development and metastasis</article-title><source>The American Journal of Pathology</source><volume>177</volume><fpage>1053</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.100105</pub-id><pub-id pub-id-type="pmid">20651229</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengyel</surname><given-names>E</given-names></name><name><surname>Burdette</surname><given-names>JE</given-names></name><name><surname>Kenny</surname><given-names>HA</given-names></name><name><surname>Matei</surname><given-names>D</given-names></name><name><surname>Pilrose</surname><given-names>J</given-names></name><name><surname>Haluska</surname><given-names>P</given-names></name><name><surname>Nephew</surname><given-names>KP</given-names></name><name><surname>Hales</surname><given-names>DB</given-names></name><name><surname>Stack</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Epithelial ovarian cancer experimental models</article-title><source>Oncogene</source><volume>33</volume><fpage>3619</fpage><lpage>3633</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.321</pub-id><pub-id pub-id-type="pmid">23934194</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lheureux</surname><given-names>S</given-names></name><name><surname>Gourley</surname><given-names>C</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Oza</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epithelial ovarian cancer</article-title><source>Lancet</source><volume>393</volume><fpage>1240</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32552-2</pub-id><pub-id pub-id-type="pmid">30910306</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litovchick</surname><given-names>L</given-names></name><name><surname>Chestukhin</surname><given-names>A</given-names></name><name><surname>DeCaprio</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Glycogen synthase kinase 3 phosphorylates RBL2/p130 during quiescence</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>8970</fpage><lpage>8980</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.20.8970-8980.2004</pub-id><pub-id pub-id-type="pmid">15456871</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llambi</surname><given-names>F</given-names></name><name><surname>Lourenço</surname><given-names>FC</given-names></name><name><surname>Gozuacik</surname><given-names>D</given-names></name><name><surname>Guix</surname><given-names>C</given-names></name><name><surname>Pays</surname><given-names>L</given-names></name><name><surname>Del Rio</surname><given-names>G</given-names></name><name><surname>Kimchi</surname><given-names>A</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The dependence receptor UNC5H2 mediates apoptosis through DAP-kinase</article-title><source>The EMBO Journal</source><volume>24</volume><fpage>1192</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600584</pub-id><pub-id pub-id-type="pmid">15729359</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Le Noble</surname><given-names>F</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>De Lafarge</surname><given-names>B</given-names></name><name><surname>Sugiyama</surname><given-names>D</given-names></name><name><surname>Bréant</surname><given-names>C</given-names></name><name><surname>Claes</surname><given-names>F</given-names></name><name><surname>De Smet</surname><given-names>F</given-names></name><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Autiero</surname><given-names>M</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M</given-names></name><name><surname>Eichmann</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system</article-title><source>Nature</source><volume>432</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nature03080</pub-id><pub-id pub-id-type="pmid">15510105</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>J</given-names></name><name><surname>Ramos-Valdes</surname><given-names>Y</given-names></name><name><surname>Perampalam</surname><given-names>P</given-names></name><name><surname>Litovchick</surname><given-names>L</given-names></name><name><surname>DiMattia</surname><given-names>GE</given-names></name><name><surname>Dick</surname><given-names>FA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A systematic analysis of negative growth control implicates the dream complex in cancer cell dormancy</article-title><source>Molecular Cancer Research</source><volume>15</volume><fpage>371</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-16-0323-T</pub-id><pub-id pub-id-type="pmid">28031411</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massagué</surname><given-names>J</given-names></name><name><surname>Ganesh</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Metastasis-initiating cells and ecosystems</article-title><source>Cancer Discovery</source><volume>11</volume><fpage>971</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-0010</pub-id><pub-id pub-id-type="pmid">33811127</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Rabizadeh</surname><given-names>S</given-names></name><name><surname>Snipas</surname><given-names>SJ</given-names></name><name><surname>Assa-Munt</surname><given-names>N</given-names></name><name><surname>Salvesen</surname><given-names>GS</given-names></name><name><surname>Bredesen</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis</article-title><source>Nature</source><volume>395</volume><fpage>801</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1038/27441</pub-id><pub-id pub-id-type="pmid">9796814</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Delloye-Bourgeois</surname><given-names>C</given-names></name><name><surname>Chédotal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Novel roles for slits and netrins: axon guidance cues as anticancer targets?</article-title><source>Nature Reviews. Cancer</source><volume>11</volume><fpage>188</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/nrc3005</pub-id><pub-id pub-id-type="pmid">21326323</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijers</surname><given-names>R</given-names></name><name><surname>Smock</surname><given-names>RG</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Netrin synergizes signaling and adhesion through DCC</article-title><source>Trends in Biochemical Sciences</source><volume>45</volume><fpage>6</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2019.10.005</pub-id><pub-id pub-id-type="pmid">31704057</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narod</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Can advanced-stage ovarian cancer be cured?</article-title><source>Nature Reviews. Clinical Oncology</source><volume>13</volume><fpage>255</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2015.224</pub-id><pub-id pub-id-type="pmid">26787282</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Network CGA</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Integrated genomic analyses of ovarian carcinoma</article-title><source>Nature</source><volume>474</volume><fpage>609</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1038/nature10166</pub-id><pub-id pub-id-type="pmid">21720365</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozmadenci</surname><given-names>D</given-names></name><name><surname>Féraud</surname><given-names>O</given-names></name><name><surname>Markossian</surname><given-names>S</given-names></name><name><surname>Kress</surname><given-names>E</given-names></name><name><surname>Ducarouge</surname><given-names>B</given-names></name><name><surname>Gibert</surname><given-names>B</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Durand</surname><given-names>I</given-names></name><name><surname>Gadot</surname><given-names>N</given-names></name><name><surname>Plateroti</surname><given-names>M</given-names></name><name><surname>Bennaceur-Griscelli</surname><given-names>A</given-names></name><name><surname>Scoazec</surname><given-names>JY</given-names></name><name><surname>Gil</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Bernet</surname><given-names>A</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Lavial</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Netrin-1 regulates somatic cell reprogramming and pluripotency maintenance</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7398</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8398</pub-id><pub-id pub-id-type="pmid">26154507</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papanastasiou</surname><given-names>AD</given-names></name><name><surname>Pampalakis</surname><given-names>G</given-names></name><name><surname>Katsaros</surname><given-names>D</given-names></name><name><surname>Sotiropoulou</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Netrin-1 overexpression is predictive of ovarian malignancies</article-title><source>Oncotarget</source><volume>2</volume><fpage>363</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.258</pub-id><pub-id pub-id-type="pmid">21789787</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peart</surname><given-names>T</given-names></name><name><surname>Ramos Valdes</surname><given-names>Y</given-names></name><name><surname>Correa</surname><given-names>RJM</given-names></name><name><surname>Fazio</surname><given-names>E</given-names></name><name><surname>Bertrand</surname><given-names>M</given-names></name><name><surname>McGee</surname><given-names>J</given-names></name><name><surname>Préfontaine</surname><given-names>M</given-names></name><name><surname>Sugimoto</surname><given-names>A</given-names></name><name><surname>DiMattia</surname><given-names>GE</given-names></name><name><surname>Shepherd</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids</article-title><source>Oncotarget</source><volume>6</volume><fpage>22424</fpage><lpage>22438</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4211</pub-id><pub-id pub-id-type="pmid">26068970</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perampalam</surname><given-names>P</given-names></name><name><surname>Dick</surname><given-names>FA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BEAVR: a browser-based tool for the exploration and visualization of RNA-seq data</article-title><source>BMC Bioinformatics</source><volume>21</volume><elocation-id>221</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-020-03549-8</pub-id><pub-id pub-id-type="pmid">32471392</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Perampalam</surname><given-names>P</given-names></name><name><surname>MacDonald</surname><given-names>JI</given-names></name><name><surname>Dick</surname><given-names>FA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>GO-CRISPR; a highly controlled workflow to discover gene essentiality</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.06.04.134841</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>TG</given-names></name><name><surname>Croucher</surname><given-names>PI</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The dormant cancer cell life cycle</article-title><source>Nature Reviews. Cancer</source><volume>20</volume><fpage>398</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/s41568-020-0263-0</pub-id><pub-id pub-id-type="pmid">32488200</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajasekharan</surname><given-names>S</given-names></name><name><surname>Kennedy</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The netrin protein family</article-title><source>Genome Biology</source><volume>10</volume><elocation-id>239</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2009-10-9-239</pub-id><pub-id pub-id-type="pmid">19785719</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recasens</surname><given-names>A</given-names></name><name><surname>Munoz</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeting cancer cell dormancy</article-title><source>Trends in Pharmacological Sciences</source><volume>40</volume><fpage>128</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.12.004</pub-id><pub-id pub-id-type="pmid">30612715</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renders</surname><given-names>S</given-names></name><name><surname>Svendsen</surname><given-names>AF</given-names></name><name><surname>Panten</surname><given-names>J</given-names></name><name><surname>Rama</surname><given-names>N</given-names></name><name><surname>Maryanovich</surname><given-names>M</given-names></name><name><surname>Sommerkamp</surname><given-names>P</given-names></name><name><surname>Ladel</surname><given-names>L</given-names></name><name><surname>Redavid</surname><given-names>AR</given-names></name><name><surname>Gibert</surname><given-names>B</given-names></name><name><surname>Lazare</surname><given-names>S</given-names></name><name><surname>Ducarouge</surname><given-names>B</given-names></name><name><surname>Schönberger</surname><given-names>K</given-names></name><name><surname>Narr</surname><given-names>A</given-names></name><name><surname>Tourbez</surname><given-names>M</given-names></name><name><surname>Dethmers-Ausema</surname><given-names>B</given-names></name><name><surname>Zwart</surname><given-names>E</given-names></name><name><surname>Hotz-Wagenblatt</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Korn</surname><given-names>C</given-names></name><name><surname>Zeisberger</surname><given-names>P</given-names></name><name><surname>Przybylla</surname><given-names>A</given-names></name><name><surname>Sohn</surname><given-names>M</given-names></name><name><surname>Mendez-Ferrer</surname><given-names>S</given-names></name><name><surname>Heikenwälder</surname><given-names>M</given-names></name><name><surname>Brune</surname><given-names>M</given-names></name><name><surname>Klimmeck</surname><given-names>D</given-names></name><name><surname>Bystrykh</surname><given-names>L</given-names></name><name><surname>Frenette</surname><given-names>PS</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>de Haan</surname><given-names>G</given-names></name><name><surname>Cabezas-Wallscheid</surname><given-names>N</given-names></name><name><surname>Trumpp</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Niche derived netrin-1 regulates hematopoietic stem cell dormancy via its receptor neogenin-1</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>608</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-20801-0</pub-id><pub-id pub-id-type="pmid">33504783</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Shalem</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved vectors and genome-wide libraries for CRISPR screening</article-title><source>Nature Methods</source><volume>11</volume><fpage>783</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3047</pub-id><pub-id pub-id-type="pmid">25075903</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>TG</given-names></name><name><surname>Thériault</surname><given-names>BL</given-names></name><name><surname>Campbell</surname><given-names>EJ</given-names></name><name><surname>Nachtigal</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients</article-title><source>Nature Protocols</source><volume>1</volume><fpage>2643</fpage><lpage>2649</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.328</pub-id><pub-id pub-id-type="pmid">17406520</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>TG</given-names></name><name><surname>Dick</surname><given-names>FA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Principles of dormancy evident in high-grade serous ovarian cancer</article-title><source>Cell Division</source><volume>17</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/s13008-022-00079-y</pub-id><pub-id pub-id-type="pmid">35321751</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sosa</surname><given-names>MS</given-names></name><name><surname>Bragado</surname><given-names>P</given-names></name><name><surname>Aguirre-Ghiso</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mechanisms of disseminated cancer cell dormancy: an awakening field</article-title><source>Nature Reviews. Cancer</source><volume>14</volume><fpage>611</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1038/nrc3793</pub-id><pub-id pub-id-type="pmid">25118602</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>JG</given-names></name><name><surname>Valdes</surname><given-names>YR</given-names></name><name><surname>Sivapragasam</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>JW</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name><name><surname>Stojdl</surname><given-names>D</given-names></name><name><surname>DiMattia</surname><given-names>GE</given-names></name><name><surname>Shepherd</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential</article-title><source>BMC Cancer</source><volume>17</volume><elocation-id>594</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-017-3600-2</pub-id><pub-id pub-id-type="pmid">28854921</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Large-scale single guide rna library construction and use for crispr-cas9-based genetic screens</article-title><source>Cold Spring Harbor Protocols</source><volume>2016</volume><elocation-id>pdb.top086892</elocation-id><pub-id pub-id-type="doi">10.1101/pdb.top086892</pub-id><pub-id pub-id-type="pmid">26933254</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>AC</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mechanisms of cancer cell dormancy--another hallmark of cancer?</article-title><source>Cancer Research</source><volume>75</volume><fpage>5014</fpage><lpage>5022</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1370</pub-id><pub-id pub-id-type="pmid">26354021</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Netrin-1 promotes gastric cancer cell proliferation and invasion via the receptor neogenin through PI3K/AKT signaling pathway</article-title><source>Oncotarget</source><volume>8</volume><fpage>51177</fpage><lpage>51189</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.17750</pub-id><pub-id pub-id-type="pmid">28881639</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanoni</surname><given-names>M</given-names></name><name><surname>Piccinini</surname><given-names>F</given-names></name><name><surname>Arienti</surname><given-names>C</given-names></name><name><surname>Zamagni</surname><given-names>A</given-names></name><name><surname>Santi</surname><given-names>S</given-names></name><name><surname>Polico</surname><given-names>R</given-names></name><name><surname>Bevilacqua</surname><given-names>A</given-names></name><name><surname>Tesei</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>19103</elocation-id><pub-id pub-id-type="doi">10.1038/srep19103</pub-id><pub-id pub-id-type="pmid">26752500</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene <break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">NTN1</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 9423 <break/>Gene Cards:<break/>GC17P100538</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene <break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">NTN3</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 4917 <break/>Gene Cards:<break/>GC17P100538</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/> (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">NTN4</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 59277 <break/>Gene Cards:<break/>GC12M095657</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene <break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">NTN5</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 126147 <break/>Gene Cards:<break/>GC19M048661</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/> (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Unc5A</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 90249 <break/>Gene Cards:<break/>GC05P185698</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/> (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Unc5B</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 219699<break/>Gene Cards:<break/>GC10P071212</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene <break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Unc5C</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 8633<break/>Gene Cards:<break/>GC04M095162</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene <break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Unc5D</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 137970 <break/>Gene Cards:<break/>GC08P035235</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/> (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Dyrk1A</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 1859 <break/>Gene Cards:<break/>GC21P037365</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene <break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">DCC</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 1630 <break/>Gene Cards:<break/>GC18P052340</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/> (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Neo1</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 4756 <break/>Gene Cards:<break/>GC15P073051</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene <break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">DSCAM</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NCBI: 1826 <break/>Gene Cards<break/>:GC21M040010</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, <break/>strain <break/>background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">Endura <break/>competent cells</td><td align="left" valign="bottom">Biosearch<break/> Technologies</td><td align="left" valign="bottom">60242-2</td><td align="left" valign="bottom">Electrocompetent <break/>cells</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">NEB10 beta</td><td align="left" valign="bottom">New England <break/>Biolabs</td><td align="left" valign="bottom">C3019H</td><td align="left" valign="bottom">High efficiency <break/>chemically <break/>Competent cells</td></tr><tr><td align="left" valign="bottom">Cell line<break/> (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">OVCAR8Ovarian <break/>cancer cell line</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL%201629">CVCL 1629</ext-link></td><td align="left" valign="bottom">Ovarian cancer cell line <break/>maintained in <italic>T.Shepherd</italic> lab</td></tr><tr><td align="left" valign="bottom">Cell line<break/> (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">OVCAR3Ovarian <break/>cancer cell line</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-161</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line <break/>(<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">TOV1946 ovarian <break/>cancer cell line</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL%204062">CVCL 4062</ext-link></td><td align="left" valign="bottom">Ovarian cancer cell line <break/>maintained in <break/><italic>R. Rottapel</italic> lab</td></tr><tr><td align="left" valign="bottom">Cell line <break/>(<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">iOvCa147Ovarian <break/>cancer cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary ovarian cancer <break/>cell line maintained in <break/><italic>T. Shepherd</italic> lab</td></tr><tr><td align="left" valign="bottom">Cell line<break/> (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">OVCAR4Ovarian <break/>cancer cell line</td><td align="left" valign="bottom">Millipore-Sigma</td><td align="left" valign="bottom">SCC258</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line <break/>(<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">COV318Ovarian <break/>cancer cell line</td><td align="left" valign="bottom">Millipore-Sigma</td><td align="left" valign="bottom">07071903-1VL</td><td align="left" valign="bottom">Primary ovarian<break/> cancer cell line</td></tr><tr><td align="left" valign="bottom">Cell line <break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Hek293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link></td><td align="left" valign="bottom">Human embryonic <break/>kidney cells</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">EOC96Ovarian <break/>cancer cells</td><td align="left" valign="bottom">London Health <break/>Sciences Centre</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fresh isolate from <break/>patient ascites</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">EOC101Ovarian <break/>cancer cells</td><td align="left" valign="bottom">London Health <break/>Sciences Centre</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fresh isolate from<break/> patient ascites</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">EOC526Ovarian <break/>cancer cells</td><td align="left" valign="bottom">London Health <break/>Sciences Centre</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fresh isolate from<break/> patient ascites</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phosphor-p44/42<break/>MAPK (Erk)Rabbit Monoclonalantibody</td><td align="left" valign="bottom">Cell Signaling<break/> technology</td><td align="left" valign="bottom">#4370<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2315112">AB_2315112</ext-link></td><td align="left" valign="bottom">WB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p44/42 MAPK(Erk)<break/>Rabbit Monoclonalantibody</td><td align="left" valign="bottom">Cell Signaling <break/>technology</td><td align="left" valign="bottom">#4695<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_390779">AB_390779</ext-link></td><td align="left" valign="bottom">WB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phosphor-p38MAPKRabbit Monoclonalantibody</td><td align="left" valign="bottom">Cell Signaling<break/> technology</td><td align="left" valign="bottom">#4511<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_AB_2139682">AB_2139682</ext-link></td><td align="left" valign="bottom">WB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p38 MAPKRabbit Monoclonalantibody</td><td align="left" valign="bottom">Cell Signaling <break/>technology</td><td align="left" valign="bottom">#9215<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331762">AB_33176</ext-link><ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331762">2</ext-link></td><td align="left" valign="bottom">WB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">a-TubulinRabbit Monoclonalantibody</td><td align="left" valign="bottom">Cell Signaling<break/> Technology</td><td align="left" valign="bottom">#2125<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2619646">AB_2619646</ext-link></td><td align="left" valign="bottom">WB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">NTN1Rabbit Monoclonalantibody</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">#Ab126729<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11131145">AB_11131145</ext-link></td><td align="left" valign="bottom">1:1000 for Western<break/> blots1:150 for IHC</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p130(RBL2)<break/>Rabbit polyclonal</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Discontinued<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_632093">AB_632093</ext-link></td><td align="left" valign="bottom">1:1000 for Western <break/>Blots1:150 for IHC</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Ki67Rabbit <break/>Monoclonalantibody</td><td align="left" valign="bottom">Cell Signaling<break/> Technology</td><td align="left" valign="bottom">#12202<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2620142">AB_2620142</ext-link></td><td align="left" valign="bottom">1:500 for IHC</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Ki67Rabbit <break/>Monoclonalantibody</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">#ab16667<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_302459">AB_302459</ext-link></td><td align="left" valign="bottom">1:1000 for Western blot</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">p53Rabbit <break/>Monoclonalantibody</td><td align="left" valign="bottom">Cell Signaling <break/>Technology</td><td align="left" valign="bottom">#2527<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10695803">AB_10695803</ext-link></td><td align="left" valign="bottom">1:120 for IHC</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">EpCAMRabbit <break/>Monoclonalantibody</td><td align="left" valign="bottom">Cell Signaling<break/> Technology</td><td align="left" valign="bottom">#93790<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2800214">AB_2800214</ext-link></td><td align="left" valign="bottom">1:150 for IHC</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Myc (9E10)Mouse <break/>Monoclonalantibody</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-40<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_627268">AB_627268</ext-link></td><td align="left" valign="bottom">WB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">NTN3</td><td align="left" valign="bottom">Gift from<break/> P. Mehlan lab</td><td align="left" valign="bottom">Not commercially <break/>available</td><td align="left" valign="bottom">1:1000 for Western<break/> Blot1:500 for IHC</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Cytokeratin 7/8Mouse Monoclonalantibody</td><td align="left" valign="bottom">Zeta <break/>Corporation</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11162687">AB_11162687</ext-link> Discontinued</td><td align="left" valign="bottom">1:250 for IHC</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phosphor Tau(S404)Rabbit Monoclonalantibody</td><td align="left" valign="bottom">Cell <break/>Siganling Technology</td><td align="left" valign="bottom">#20194<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2798837">AB_2798837</ext-link></td><td align="left" valign="bottom">WB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">TauRabbit Monoclonalantibody</td><td align="left" valign="bottom">Cell Signaling<break/> Technology</td><td align="left" valign="bottom">#46687<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2783844">AB_2783844</ext-link></td><td align="left" valign="bottom">WB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">DYRK1ARabbit Polyclonalantibody</td><td align="left" valign="bottom">Cell Signaling<break/> Technology</td><td align="left" valign="bottom">#2771<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_915851">AB_915851</ext-link></td><td align="left" valign="bottom">WB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">b-ActinRabbit Polyclonalantibody</td><td align="left" valign="bottom">Millipore<break/> Sigma</td><td align="left" valign="bottom">#A2066<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_476693">AB_476693</ext-link></td><td align="left" valign="bottom">WB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG Biotinylated</td><td align="left" valign="bottom">Jackson<break/> ImmunoResearch</td><td align="left" valign="bottom">#115-067-003<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2338586">AB_2338586</ext-link></td><td align="left" valign="bottom">IHC 1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-rabbit IgG Biotinylated</td><td align="left" valign="bottom">Vector<break/> Laboratories</td><td align="left" valign="bottom">#BP-9100-50</td><td align="left" valign="bottom">IHC 1:500</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">Human GeCKO<break/>Lentiviral sgRNA library V2LentiGuide Puro</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#1000000049</td><td align="left" valign="bottom">Human whole genome<break/> CRISPR library</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">Lenti-CAS9-Blast</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#52962<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_52962">Addgene_52962</ext-link></td><td align="left" valign="bottom">Lentiviral vector for<break/> delivery of CAS9</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">pLentiCRISPR-Puro-V2</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#52961<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_52961">Addgene_52961</ext-link></td><td align="left" valign="bottom">Lentiviral vector for<break/> delivery of sgRNA</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSPCAS9-(BB)2A-GFP(pX458)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#48138<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_48138">Addgene_48138</ext-link></td><td align="left" valign="bottom">Vector for delivery<break/> of sgRNA</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">NTN1-FC-His</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#72104<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_72104">Addgene_72104</ext-link></td><td align="left" valign="bottom">Plasmid carrying full<break/> length Murine NTN1 <break/>fused to the FC portion of IgG</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">NTN3-FC-His</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#72105<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_72105">Addgene_72105</ext-link></td><td align="left" valign="bottom">Plasmid carrying full length<break/> Murine NTN3 <break/>fused to the FC portion of IgG</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">FutdTW</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">#22478<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_22478">Addgene_22478</ext-link></td><td align="left" valign="bottom">Lentiviral expression <break/>vector</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">FutdTW NTN1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector expressing <break/>full length Murine NTN1</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">FutdTW NTN3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector expressing<break/> full length Murine NTN3</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">pcDNA3.1myc/His A</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">V80020</td><td align="left" valign="bottom">Mammalian expression vector</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">pcDNA3.1myc/His ANTN1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Mammalian <break/>expression <break/>vectorfor the <break/>expression <break/>of NTN1 under G418 selection</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">pcDNA3.1myc/His ANTN3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Mammalian <break/>expression vector <break/>for the expression of <break/>NTN3 under G418 selection</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN1_A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector <break/>for the delivery of, <break/>sgRNA targeting <break/>human NTN1</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN1_B</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the <break/>delivery of <break/>sgRNA targeting<break/> human NTN1</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN1_C</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for<break/> the delivery of <break/>sgRNA targeting <break/>human NTN1</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN3_1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for<break/> the delivery of <break/>sgRNA targeting<break/> human NTN3</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN3_2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector <break/>for the delivery of <break/>sgRNA targeting<break/> human NTN3</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN3_3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for<break/> the delivery of <break/>sgRNA targeting<break/> human NTN3</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN4_A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for<break/> the delivery of <break/>sgRNA targeting<break/> human NTN4</td></tr><tr><td align="left" valign="bottom">recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN4_B</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for<break/> the delivery of <break/>sgRNA targeting <break/>human NTN4</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN5_A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for<break/> the delivery of <break/>sgRNA targeting<break/> human NTN5</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN5_B</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting human NTN5</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2NTN5_C</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting <break/>human NTN5</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5A_1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting<break/> human Unc5A</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5A_2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting <break/>human Unc5A</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5A_3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting <break/>human Unc5A</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5B_1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting<break/> human Unc5B</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5B_2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting<break/> human Unc5B</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5B_3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting <break/>human Unc5B</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5C_1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting <break/>human Unc5C</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5C_2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting<break/> human Unc5C</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5C_3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting<break/> human Unc5C</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5D_1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting<break/> human Unc5D</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5D_2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting<break/> human Unc5D</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Unc5D_3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of<break/> sgRNA targeting <break/>human Unc5D</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2DCC_1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting human DCC</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2DCC_2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting human DCC</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2DCC_3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting<break/> human DCC</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Neo1_1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the deliveryof <break/>sgRNA targeting<break/> human Neo1</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Neo1_2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting<break/> human Neo1</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2Neo1_3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting<break/> human Neo1</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2DSCAM_1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the deliveryof <break/>sgRNA targeting<break/> human DSCAM</td></tr><tr><td align="left" valign="bottom">Recombinant<break/> DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2DSCAM_2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the deliveryof <break/>sgRNA targeting <break/>human DSCAM</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">LentiCRISPRV2DSCAM_3</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lentiviral vector for the delivery of <break/>sgRNA targeting <break/>human DSCAM</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN1-AsgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-GCAGTCGTCGG<break/>CGGCGCTAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN3-AsgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CGACTGTCCGG<break/>CCGCCGCAG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN4-AsgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CACATTAACGT<break/>CGAAGTGAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN5-AsgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-ATCGTAGCATG<break/>GGTCCGCAG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5A-1sgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CTGTGCTGCG<break/>CTCGATCACG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5B-1sgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CGTACAGGCG<break/>ATGCGGACGT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5C-1sgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-TCCCTTCAGG<break/>TGGTCGACAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5D-1sgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CTTACAGGCTA<break/>TGCGCACAG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DCC-1sgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-GACTTCCTCG<break/>CCTCGTAACC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Neo1-1sgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CGGGCTTTAT<break/>CGCTGCGTAG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DSCAM-1sgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomic<break/>CRISPRLibrary V2</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-ATCGTAGATC<break/>TCCTCGCCCG-3’</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant Human Netrin-1</td><td align="left" valign="bottom">R and D<break/> Systems</td><td align="left" valign="bottom">#6419-N1</td><td align="left" valign="bottom">500 ng/ml</td></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Monarch DNA Gel Extraction Kit</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#T1020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Monarch total RNA Miniprep Kit</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#T2010</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Monarch PCR DNA Cleanup kit</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#T1030</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">NEBNext Ultra II Q5 Master Mix</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#MO544</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Monarch Plasmid MiniPrep Kit</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#T1010</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">DNeasy Blood and <break/>Tissue DNA isolation kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">#69504</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial<break/> assay or kit</td><td align="left" valign="bottom">NextSeq 75 Cycle <break/>NG sequencing kit</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">#20024906</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">iScript cDNA <break/>Synthesis Kit</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">#1708890</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">iQ SYBR Green <break/>Supermix</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">#1708882</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">RNA 6000 Nano Kit</td><td align="left" valign="bottom">Agilent <break/>Technologies</td><td align="left" valign="bottom">#5067-1511</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial<break/> assay or kit</td><td align="left" valign="bottom">ScriptSeq Complete <break/>Gold Kit</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">#BEP1206</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial<break/> assay or kit</td><td align="left" valign="bottom">NextSeq 500Mid-Output150 cycles</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">#20024907</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Trematinib</td><td align="left" valign="bottom">Selleckchem</td><td align="left" valign="bottom">#S4484</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Polybrene</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-134220</td><td align="left" valign="bottom">8 mg/ml</td></tr><tr><td align="left" valign="bottom">Chemical<break/> compound, drug</td><td align="left" valign="bottom">Crystal Violet</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">#C6158</td><td align="left" valign="bottom">0.50%</td></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Protease inhibitor <break/>cocktail</td><td align="left" valign="bottom">Cell <break/>Signaling<break/>Technology</td><td align="left" valign="bottom">#5871S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phospahtase <break/>inhibitor cocktail</td><td align="left" valign="bottom">Cell <break/>Signaling<break/>Technology</td><td align="left" valign="bottom">#5870S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Graphpad</td><td align="left" valign="bottom">Prism</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Image Lab</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014210">SCR_014210</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Aperio ImageScope</td><td align="left" valign="bottom">Leica</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_020993">SCR_020993</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SAMTOOLS</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://htslib.org">htslib.org</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002105">SCR_002105</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Illumina Sequencing <break/>HUB (BaseSpace)</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_011881">SCR_011881</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Cutadapt</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://code.google.com/archive/redirect/a/code.google.com">code.google.com/p/cutadapt/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_011841">SCR_011841</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Bowtie 2</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bowtie-bio.sourceforge.net/bowtie2/index.shtml">bowtie-bio.sourceforge.net/bowtie2/index.shtml</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016368">SCR_016368</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ConsensusPathDB</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cpdb.molgen.mpg.de/">Cpdb.molgen.mpg.de</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002231">SCR_002231</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Reactome</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://reactome.org/">https://reactome.org/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003485">SCR_003485</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MAGeCK</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/projects/mageck/">https://sourceforge.net/projects/mageck/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">STAR2.6.1a</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://code.google.com/archive/p/rna-star/">https://code.google.com/archive/p/rna-star/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_004463">SCR_004463</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DESeq2</td><td align="left" valign="bottom"><break/><ext-link ext-link-type="uri" xlink:href="http://bioconducter.org/packages/release/bioc/html/DESeq2/html">http://bioconducter.org/packages/release/bioc/html/DESeq2/html</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015687">SCR_015687</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CBioPortal</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://cbioportal.org">cbioportal.org</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014555">SCR_014555</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">The Cancer<break/>Genome Atlas (TCGA)</td><td align="left" valign="bottom">cancergenome.nih.gov</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003193">SCR_003193</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R 3.6.2</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_001905">SCR_001905</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">BEAVR</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/developerpiru/BEAVR">https://github.com/developerpiru/BEAVR</ext-link>; <ext-link ext-link-type="uri" xlink:href="https://hub.docker.com/r/pirunthan/beavr">https://hub.docker.com/r/pirunthan/beavr</ext-link>; <xref ref-type="bibr" rid="bib52">Perampalam and Dick, 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">BMC Bioinformatics. <break/>2020 May 29;21(1):221.</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Streptavidin HRP</td><td align="left" valign="bottom">Vector<break/> Laboratories</td><td align="left" valign="bottom">#SA-5704-100</td><td align="left" valign="bottom">Secondary for IHCSee Methods, <break/>Histology and <break/>immunohisto-chemistry</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">ImmPACT DAB</td><td align="left" valign="bottom">Vector<break/> Laboratories</td><td align="left" valign="bottom">#SK-4105</td><td align="left" valign="bottom">Chromophore for IHCSee Methods,<break/> Histology and<break/> immunohisto-chemistry</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">VectaMount</td><td align="left" valign="bottom">Vector <break/>Laboratories</td><td align="left" valign="bottom">#H-5700-60</td><td align="left" valign="bottom">Mounting materialfor<break/> IHC glass slides <break/>See Methods, Histology and <break/>immunohisto-chemistry</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Hematoxylin</td><td align="left" valign="bottom">Millipore <break/>Sigma</td><td align="left" valign="bottom">#HHS32-1L</td><td align="left" valign="bottom">Counterstain reagentFor IHCSee Methods, <break/>Histology and<break/> immunohisto-chemistry</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Eosin Y</td><td align="left" valign="bottom">Millipore <break/>Sigma</td><td align="left" valign="bottom">#E4009</td><td align="left" valign="bottom">Common stain in conjunction<break/> with hematoxylinfor IHC of tissue <break/>See Methods, <break/>Histologyand immunohisto-chemistry</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Gibson Assembly Mastermix</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#E2611</td><td align="left" valign="bottom">See “Methods” <break/>Generation of<break/> Knockout Lines</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Dynabeads</td><td align="left" valign="bottom">Thermo-Fisher</td><td align="left" valign="bottom">#10003D</td><td align="left" valign="bottom">See Methods, <break/>Dyrk1AIP kinase assay</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">BsmB1</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#R0739</td><td align="left" valign="bottom">Restriction endonucleasefor <break/>construction of CRISPR constructs</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">EcoRV</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#R0195</td><td align="left" valign="bottom">Restriction endonuclease for<break/> construction of pcDNA NTN1. See<break/> “Methods”Generation of<break/> Overexpression cell lines</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">XbaI</td><td align="left" valign="bottom">New England <break/>Biolabs</td><td align="left" valign="bottom">#R0145</td><td align="left" valign="bottom">Restriction endonuclease for<break/> construction of pcDNA NTN1. <break/>See “Methods”Generation <break/>of Overexpression cell lines</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">NotI</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#R3189</td><td align="left" valign="bottom">Restriction endonuclease for<break/> construction of pcDNA NTN3. <break/>See “Methods”Generation<break/> of Overexpression cell lines</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">BamH1</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#R0136</td><td align="left" valign="bottom">Restriction endonuclease for<break/> construction of FutdTWNTN1 <break/>and NTN3. See <break/>“Methods”Generation of <break/>Overexpression cell lines</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">EcoRI</td><td align="left" valign="bottom">New England<break/> Biolabs</td><td align="left" valign="bottom">#R0101</td><td align="left" valign="bottom">Restriction endonucleasefor <break/>construction of FutdTWNTN1<break/> and NTN3.<break/>See “Methods”Generation of <break/>Overexpression cell lines</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">v2.1-F1</td><td align="left" valign="bottom">TKO<break/> libraryProtocols<break/>Addgene#90294</td><td align="left" valign="bottom">PCR Primer for gen<break/>omic amplification of CRISPR guides <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-GAGGGCCTATT<break/>TCCCATGATTC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">v2.1-R1</td><td align="left" valign="bottom">TKO<break/> libraryProtocols<break/>Addgene#90294</td><td align="left" valign="bottom">PCR Primer for ge<break/>nomic amplification<break/> of CRISPR guides <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-GTTGCGAAAAA<break/>GAACGTTCACGG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D501 -F</td><td align="left" valign="bottom">TKO<break/> libraryProtocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-AATGATACGGCGACCACC<break/>GAGATCTACACTATAG<break/>CCTACACTCTTTCCCTACA<break/>CGACGCTCTTCCGAT<break/>CTTTGTGG<break/>AAAGGACGAAACACCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D502-F</td><td align="left" valign="bottom">TKO<break/> libraryProtocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-AATGATACGGCGACCA<break/>CCGAGATCTACACATAGA<break/>GGCACACTCTTTCCCTA<break/>CACGACGCTCTTCCGAT<break/>CTTTGTGGA<break/>AAGGACGAAACACCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D503-F</td><td align="left" valign="bottom">TKO<break/> libraryProtocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-AATGATACGGCGACCA<break/>CCGAGATCTACACCCT<break/>ATCCTACACTCTTTCCCT<break/>ACACGACGCTCTTCCG<break/>ATCTTTGTGGA<break/>AAGGACGAAACACCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D504-F</td><td align="left" valign="bottom">TKO<break/> libraryProtocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-AATGATACGGCGACCACC<break/>GAGATCTACACGGCT<break/>CTGAACACTCTTTCCCTA<break/>CACGACGCTCTTCCG<break/>ATCTTTGTGG<break/>AAAGGACGAAACACCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D505-F</td><td align="left" valign="bottom">TKO libraryProtocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer<break/><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-AATGATACGGCGACCA<break/>CCGAGATCTACACAGGC<break/>GAAGACACTCTTTCCCTA<break/>CACGACGCTCTTCCGAT<break/>CTTTGTGGA<break/>AAGGACGAAACACCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D506-F</td><td align="left" valign="bottom">TKO<break/> library<break/>Protocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer<break/><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-AATGATACGGCGACCA<break/>CCGAGATCTACACTAA<break/>TCTTAACACTCTTTCCCTA<break/>CACGACGCTCTTCCG<break/>ATCTTTGTG<break/>GAAAGGACGAAACACCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D701-R</td><td align="left" valign="bottom">TKO<break/> library<break/>Protocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer<break/><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-CAAGCAGAAGACGG<break/>CATACGAGATCGAGTAA<break/>TGTGACTGGAGTTCAGA<break/>CGTGTGCTCTTCCGAT<break/>CTACTTGCTAT<break/>TTCTAGCTCTAAAAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D702-R</td><td align="left" valign="bottom">TKO<break/> library<break/>Protocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer<break/><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-AATGATACGGCGACCA<break/>CCGAGATCTACACATAGA<break/>GGCACACTCTTTCCCTA<break/>CACGACGCTCTTCCGAT<break/>CTTTGTGG<break/>AAAGGACGAAACACCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D704-R</td><td align="left" valign="bottom">TKO library<break/>Protocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer<break/><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-CAAGCAGAAGACGGCA<break/>TACGAGATGGAATCTCGT<break/>GACTGGAGTTCAGACGT<break/>GTGCTCTTCCGATCTAC<break/>TTGCTATTTCTA<break/>GCTCTAAAAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D705-R</td><td align="left" valign="bottom">TKO<break/> libraryProtocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer<break/><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-CAAGCAGAAGACGGCAT<break/>ACGAGATTTCTGAATGTG<break/>ACTGGAGTTCAGACGTGTG<break/>CTCTTCCGATCTACTTG<break/>CTATTTCTA<break/>GCTCTAAAAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D706-R</td><td align="left" valign="bottom">TKO<break/> libraryProtocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer<break/><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-CAAGCAGAAGACGGCAT<break/>ACGAGATACGAATTCGT<break/>GACTGGAGTTCAGACGTGTGCTCT<break/>TCCGATCTAC<break/>TTGCTATTTCTAGCTCTAAAAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">D707-R</td><td align="left" valign="bottom">TKO<break/> libraryProtocols<break/>Addgene#90294</td><td align="left" valign="bottom">Indexing Primer <break/><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link><break/></td><td align="left" valign="bottom">5’-CAAGCAGAAGACGG<break/>CATACGAGATAGCTTCAGGT<break/>GACTGGAGTTCAGAC<break/>GTGTGCTCTTCCGATCTAC<break/>TTGCTATTTCTAG<break/>CTCTAAAAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Dyrk1A sgRNA-A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5'-CTCACTTAT<break/>CTTCTTGTAGG-3'</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Dyrk1A sgRNA-B</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5'-GCAACGTG<break/>GGATTATGGATT-3'</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN1-BsgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-ACCCGTCAC<break/>GCCGTCCTTGC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN1-CsgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5'-TATCGGCCA<break/>CGATGCCGCTC-3'</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN3-BsgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-GGTCTCGAT<break/>AGAAGCCCTCC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN3-CsgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-ACCTGCAAC<break/>CGCTGCGCGCC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN4-BsgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CGCAGGTC<break/>ACGATAGAAGCC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN5-BsgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-GCCGCCCG<break/>TCCCATCGAGAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN5-CsgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-GGCCTGAC<break/>CTGCAACCGCTG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5A-2sgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CGCCCG<break/>CGGCCATGGCCGTC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5A-3sgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-GTCCTCGCCG<break/>CTTGGCTCCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5B-2sgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-TTCACAAT<break/>GTAGGCGTCCTG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5B-3sgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CCTGTGTGA<break/>CGTGGTCGTTC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5C-2sgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-TGAGATTT<break/>CGCGCCAGCAAG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5C-3sgRNA</td><td align="left" valign="bottom">GeCKO genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CAATGCGC<break/>ACATACGCCTTC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5D-2sgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-GCGCTTA<break/>CCTCGGGCAGCCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5D-3sgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CAGAGACGT<break/>GCTCGTTCTGA-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DCC-2sgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-AAATTCCAA<break/>TGTCCCCCGGT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DCC-3sgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-GCAGATCA<break/>GCCGACTCCAAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Neo1-2sgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-GAACCTTC<break/>CTCAGTTTATGC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Neo1-3sgRNA</td><td align="left" valign="bottom">GeCKO genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-TGTTTCCCA<break/>CGTAACAGTGA-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DSCAM-2sgRNA</td><td align="left" valign="bottom">GeCKO <break/>genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-AGTGATGTAC<break/>GCCTCCACCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DSCAM-3sgRNA</td><td align="left" valign="bottom">GeCKO<break/> genomicCRISPRLibrary V2Addgene#1000000049</td><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-GGAGCCCTAT<break/>ACAGTCCGTG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Dyrk1A Exon2 F</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR prime</td><td align="left" valign="bottom">5’-GGTTTCACCT<break/>GGTTTGGGGA-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Dyrk1A Exon2 R</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR prime</td><td align="left" valign="bottom">5’-TCCGTGGG<break/>CAAGAAACTTT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5A-FqRCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-GCTGAGGCGC<break/>TAAAGCCGCCCTC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5A-RqRCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-ACCTGCTGCCT<break/>TGAGACATTAATGC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5B-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-CCCGCCACA<break/>CAGATCTACTT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5B-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-CAGTAATCC<break/>TCCAGCCCAAA-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5C_1-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-GCAAATTGCTG<break/>GCTAAATATCAGGAA-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5C_1-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-GCTCCACTGTGT<break/>TCAGGCTAAATCTT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5C_2-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-AATTGATCC<break/>CGTTGAAGATCGG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5C_2-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-TGACAGTGG<break/>CAGTTGTACTTTT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5D_1-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-CAAGAGCAA<break/>CCCTATTGCACT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5D_1-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-CTCGTTCTG<break/>ATGGACCCACT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5D_2-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-CAAGAGCAA<break/>CCCTATTGCACT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Unc5D_2_RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-AAGCCCTTCC<break/>CGAATCCATC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN1-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-TGCAAGAAGG<break/>ACTATGCCGTC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN1-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-GCTCGTGCCC<break/>TGCTTATACAC-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN3-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-TGCAAGCCCT<break/>TCTACTGCGACA-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN3-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-CAGTCGGTA<break/>CAGCTCCATGTTG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN4-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5'-CAGAAGGACAG<break/>TATTGCCAGAGG-3'</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN4-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5'-GCAGAAGGTC<break/>ACTGAGTTGGCA-5'</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN5-FqPCRprimer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5'-CTTGCCACTA<break/>CTCCTGGTGCTT-3'</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN5-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5'-AGTACCTC<break/>CGAAGGCTCATGTG-3'</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DCC_1-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-GACTTTACCAAT<break/>GTGAGGCATCT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DCC_1-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-GGTCCTGCT<break/>ACTGCAACTTTT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DCC_2-FqPCRprimer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-GAGACACA<break/>GTGCTACTCAAGTG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DCC_2-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-GGAGTCAGG<break/>TCTTGTTGGTTCTT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DSCAM_1-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-TTGCGGTCT<break/>TCAAGTGCATTA-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DSCAM_1-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-TGCAGCGGTAGTTATACAATCCA-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DSCAM_2-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-ATCAGACCCAGCGAACTCAG-5’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DSCAM_2-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-CCAGCGGTAATCTGGCTCAG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Neo-1-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-GTCACTGAGACCTTGGTAAGCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Neo-1-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5’-TCAGCAGACAGCCAGTCAGTTG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">GAPDH-FqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5'-CGGAGTCAACGGATTTGGTCGTAT-3'</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">GAPDH-RqPCR primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom">5'-AGCCTTCTCCATGGTGGTGAAGAC-3'</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN1-F cloning primer_1</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cloning primer</td><td align="left" valign="bottom">5’- GCTATCGATATCCCAAACG<break/>CCACCATGATGCGCGC<break/>TGTGTGGGAGGCGCTG -3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN1-Rcloning primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cloning primer</td><td align="left" valign="bottom">5’- GCTATCCTCGAGGGCCTTCTTGCAC<break/>TTGCCCTTCTTCTCCCG -3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN3-Fcloning primer_1</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cloning primer</td><td align="left" valign="bottom">5’-GCTAGCGCGGCCGCCACCATGC<break/>CTGGCTGGCCCTGG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN3-Rcloning primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cloning primer</td><td align="left" valign="bottom">5’- ACGCGTGAATTCTTATCAA<break/>CCGGTATGCATATTCA<break/>GATCCTCTTCTGAGAT -3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN1-Fcloning primer_2</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cloning primer</td><td align="left" valign="bottom">5’-CACTGTAGATCTCCAAACGC<break/>CACCATGATGCGCGCTG<break/>TGTGGGAGGCGCTG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN3-FCloning primer_2</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cloning primer</td><td align="left" valign="bottom">5’-CTCGAGATCTGCGGCCGCCACC<break/>ATGCCTGGCTGGCCCTGG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">NTN1_NTN3Cloning reverse primer</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cloning primer</td><td align="left" valign="bottom">5’-ACGCGTGAATTCTTATCAA<break/>CCGGTATGCATATTCA<break/>GATCCTCTTCTGAGAT-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">LacZ control CRISPR guide</td><td align="left" valign="bottom"/><td align="left" valign="bottom">CRISPR guide</td><td align="left" valign="bottom">5’-CCCGAATCTCTA<break/>TCGTGCGG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">PSMD1-1</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fitness gene<break/> CRISPR guide<break/> <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-TGTGCGCTACG<break/>GAGCTGCAA-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">PSMD1-5</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fitness gene <break/>CRISPR guide<break/> <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-ACCAGAGCCAC<break/>AATAAGCCA-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">EIF3D</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fitness gene <break/>CRISPR guide<break/> <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-ACCGACTTCAAC<break/>TGAAGAGTCTCG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">PSMB2</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Fitness gene <break/>CRISPR guide<break/> <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.11.015">http://dx.doi.org/10.1016/j.cell.2015.11.015</ext-link></td><td align="left" valign="bottom">5’-AATATTGTCCAGA<break/>TGAAGGA-3’</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91766.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Topisirovic</surname><given-names>Ivan</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Jewish General Hospital</institution><country>Canada</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>The authors further corroborated their model that Netrin signaling promotes survival and dissemination of non-proliferating ovarian cancer cells. These <bold>valuable</bold> results were found to be of significant potential interest to cancer biologists in as much as they address gaps in knowledge pertinent to the mechanisms underpinning ovarian cancer spread. In general, it was thought that <bold>solid</bold> experimental evidence was provided to support the role of Netrin signaling in fueling ovarian cancer progression.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91766.3.sa1</article-id><title-group><article-title>Joint public review:</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In this article, the authors employed modified CRISPR screens [&quot;guide-only (GO)-CRISPR&quot;] in the attempt to identify the genes which may mediate cancer cell dormancy in the high grade serous ovarian cancer (HGSOC) spheroid culture models. Using this approach, they observed that abrogation of several of the components of the netrin (e.g., DCC, UNC5Hs) and MAPK pathways compromise survival of non-proliferative ovarian cancer cells. This strategy was complemented by the RNAseq approach which revealed that number of the components of the netrin pathway are upregulated in non-proliferative ovarian cancer cells, and that their overexpression is lost upon disruption of DYRK1A kinase that has been previously demonstrated to play a major role in survival of these cells. Perampalam et al. then employed a battery of cell biology approaches to support the model whereby the Netrin signaling governs the MEK-ERK axis to support survival of non-proliferative ovarian cancer cells. Moreover, the authors show that overexpression of Netrins 1 and 3 bolsters dissemination of ovarian cancer cells in the xenograft mouse model, while also providing evidence that high levels of the aforementioned factors are associated with poor prognosis of HGSOC patients.</p><p>Strengths:</p><p>In this valuable study Perampalam et al. developed a CRISPR-based screening approach to identify key genes that are enriched in high grade serous ovarian cancer spheroids. This led to a discovery that Netrin signaling plays a prominent role in survival of ovarian cancer cells. During revision, the authors provide additional evidence to support their central claims and to this end, it was found that they now provide solid evidence to substantiate the proposed model. This work is anticipated to be of interest to cancer biologists specializing in ovarian cancer biology.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91766.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Perampalam</surname><given-names>Pirunthan</given-names></name><role specific-use="author">Author</role><aff><institution>Western University</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>MacDonald</surname><given-names>James I</given-names></name><role specific-use="author">Author</role><aff><institution>Western University</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Zakirova</surname><given-names>Komila</given-names></name><role specific-use="author">Author</role><aff><institution>Western University</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Passos</surname><given-names>Daniel T</given-names></name><role specific-use="author">Author</role><aff><institution>Western University</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Wasif</surname><given-names>Sumaiyah</given-names></name><role specific-use="author">Author</role><aff><institution>Western University</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Ramos-Valdes</surname><given-names>Yudith</given-names></name><role specific-use="author">Author</role><aff><institution>Western University</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Hervieu</surname><given-names>Maeva</given-names></name><role specific-use="author">Author</role><aff><institution>Cancer Center of Lyon</institution><addr-line><named-content content-type="city">Lyon</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Mehlen</surname><given-names>Patrick</given-names></name><role specific-use="author">Author</role><aff><institution>Centre de Cancérologie de Lyon</institution><addr-line><named-content content-type="city">Lyon</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Rottapel MD</surname><given-names>Robert</given-names></name><role specific-use="author">Author</role><aff><institution>Princess Margaret Cancer Centre, University Health Network</institution><addr-line><named-content content-type="city">Ontario</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Gibert</surname><given-names>Benjamin</given-names></name><role specific-use="author">Author</role><aff><institution>Centre de Cancérologie de Lyon</institution><addr-line><named-content content-type="city">Lyon</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Correa</surname><given-names>Rohann JM</given-names></name><role specific-use="author">Author</role><aff><institution>Western University</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Shepherd</surname><given-names>Trevor G</given-names></name><role specific-use="author">Author</role><aff><institution>Western University</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff></contrib><contrib contrib-type="author"><name><surname>Dick</surname><given-names>Fred</given-names></name><role specific-use="author">Author</role><aff><institution>Western University</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>Canada</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>Perampalam et al. describe novel methods for genome-wide CRISPR screening to identify and validate genes essential for HGSOC spheroid viability. In this study, they report that Netrin signaling is essential for maintaining disseminated cancer spheroid survival, wherein overexpression of Netrin pathway genes increases tumor burden in a xenograft model of ovarian cancer. They also show that high netrin expression correlates with poor survival outcomes in ovarian cancer patients. The study provides insights into the biology of netrin signaling in DTC cluster survival and warrants development of therapies to block netrin signaling for treating serous ovarian cancer.</p><p>Strengths:</p><p>- The study identifies Netrin signaling to be important in disseminated cancer spheroid survival</p><p>- A Novel GO-CRISPR methodology was used to find key genes and pathways essential for disseminated cancer cell survival</p></disp-quote><p>Thanks for the endorsement of our work and its importance to metastasis in ovarian cancer.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>- The term dormancy is not fully validated and requires additional confirmation to claim the importance of Netrin signaling in &quot;dormant&quot; cancer survival.</p><p>- Findings shown in the study largely relate to cancer dissemination and DTS survival rather than cancer dormancy.</p></disp-quote><p>Much of the validation of dormancy and cell cycle arrest in HGSOC spheroids, as well as the culture model, have been published previously and hence was not repeated here. I think this reviewer will appreciate the updated citations and explanations to better illustrate the state of knowledge. We have also added new experiments that further emphasize the dormant state of spheroid cells in culture and xenografts, as well as patient derived spheroids used in this study.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for Authors):</bold></p><p>(1) It is unclear what spheroid/adherent enrichment ratio is and how it ties into genes affecting cell viability. Why is an ER below 1 the criteria for selecting survival genes?</p></disp-quote><p>Our screen uses the ‘guide only’ comparison in each culture condition to establish a gene score under that specific condition. A low adherent score captures genes that are essential under standard culture conditions where cells are proliferating and this can include genes needed for proliferation or other basic functions in cell physiology. A low spheroid score identifies the genes that are most depleted in suspension when cells are growth arrested and this is an indication of cell death in this condition. Since gene knock outs are first established in adherent proliferating conditions, essential genes under these conditions will already start to become depleted from the population before suspension culture. By selecting genes with a ratio of &lt;1 we can identify those that are most relevant to dormant suspension culture conditions. Ultimately, the lowest enrichment ratio scores represent genes whose loss of function is dispensable in the initial adherent condition, but critical for survival in suspension and this is what we aimed to identify. We’ve updated Figure 1B to illustrate this and we’ve updated the explanation of the enrichment ratio on page 6, lines 144 to 147 of the results.</p><disp-quote content-type="editor-comment"><p>(2) The WB for phospho-p38 in figure 1A for OVCAR8 line does not show increased phosphorylation in the spheroid relative to the adherent. If anything, phospho-p38 appears to be reduced in the spheroid. Can the authors provide a better western blot?</p></disp-quote><p>We’ve updated this blot with a longer exposure, see Figure 1A. Phosphorylation levels of p38 are essentially unchanged in OVCAR8 cells in suspension culture, although the overall levels of p38 may be slightly reduced in dormant culture conditions.</p><disp-quote content-type="editor-comment"><p>(3) How did the authors confirm dormancy apart from western blot for phospho-ERK vs phospho-p38? Authors should add EdU/BrdU staining and/or Ki67 staining to confirm dormancy.</p></disp-quote><p>Previous publications that appear as citations 7,10, and 33 in the reference list established the growth arrest state of these cells in suspension culture in the past. This included measuring other known markers of dormancy and quiescence such as p27, p130, and reduced cyclin/cdk activity and 3H-thymidine incorporation. In addition, other associated characteristics of dormancy such as EMT and catabolic metabolism have been demonstrated in these culture conditions (see citation 11 and Rafehi et al. Endocr. Relat. Cancer 23;147-59). We’ve added these additional citations to our descriptions of dormant spheroid culture to better clarify the status of these cells in our experiments (see page 6, lines 126-28). To ensure that cells are growth arrested in the experiments shown in this paper, we have updated Figure 1A to include blots of p130 and Ki67 to further emphasize that spheroid cells are not proliferating as the quiescence marker (p130) is high and the proliferative marker (Ki67) is lost in suspension culture.</p><disp-quote content-type="editor-comment"><p>(4) Can the authors report spheroid volume over time in culture? How was viability measured?</p></disp-quote><p>We’ve updated the methods (see page 27, line 574) to better highlight the description of cell survival that answers both of these questions. At the ends of experimental time points in both the screen and viability assays we captured live cells by replating on adherent plasticware. We fixed and stained with crystal violet and photographed plates to illustrate the sizes of spheroids (shown in Fig. 2 Supplement 1E, Fig. 6C, and 7D). We subsequently extracted the dye and quantitated it spectrophotometrically to quantitatively compare biomass of viable cells between experiments irrespective of the relatively random shapes of spheroids. We found reattachment and staining in this manner to match traditional viability assays such as CellTiter-Glo in a previous paper (10). Furthermore, biomass never increases in culture and diminishes gradually over time in culture consistent with the non-proliferative state of these experiments. Double checks of this equivalency of viability and reattached biomass measurments, as well as demonstrating that biomass is lost over time, are shown in Fig. 2 Supplement 1E that compares reattached crystal violet staining measurements with CellTiter-Glo for DYRK1A knock out cells over time in culture. In addition, we include a comparison of crystal violet staining of reattached spheroids with trypan blue dye exclusion in Fig. 5G and H. In both cases reattachment and more direct viability assays demonstrate the same conclusion that Netrin signaling supports viability in dormant culture.</p><disp-quote content-type="editor-comment"><p>(5) Please show survival significance of Netrin signaling genes in recurrence/relapse free survival to claim importance in cancer dormancy.</p></disp-quote><p>See Fig. 7 Supplement 1C where we include the recurrence free survival data. Netrin-1, and -3 high expressors also have a numerically shorter progression free survival but it is not statistically significant. Netrin-1 overexpression alone is also shown and it shows shorter survival with a P-value of 0.0735. Elevated survival of dormant cells in a residual disease state is expected to increase the chance of relapse and shorten this interval. Thus, this data is consistent with our model, but lacks statistical significance.</p><p>There are many alternative ways to interpret what shorter progression free survival, or overall survival, may mean biologically. Since survival of dormant cells is but one of them, we also added new data to experimentally investigate the role of endogenous Netrin signaling in dormant residual disease in Fig. 6 and described on page 12, lines 266-87. We used xenograft experiments to show OVCAR8 spheroids form and withdraw from the cell cycle equivalently to suspension culture following intraperitoneal injection. Furthermore, loss of Netrin signaling due to receptor deletions compromises survival during this early window before disseminated lesions form. This argues that Netrin signaling contributes to survival during this window of dormancy. In addition, mice engrafted with mutant cells experience prolonged survival when Netrin signaling is blocked. Together, these experiments further argue that Netrin signaling supports survival in the dormant, non-proliferative phase, and leads to reduced survival of mice.</p><disp-quote content-type="editor-comment"><p>(6) The authors show IHC staining of patient ascites derived HGSOC spheroids. However, no marker for dormancy is shown in these spheroids. Adding Ki67 staining or phospho-ERK vs phospho-p38 would be necessary to confirm cancer dormancy.</p></disp-quote><p>We have added new staining for Ki67 and p130 that compares these markers in HGSOC tumors where Ki67 is high and p130 is low with ascites derived spheroids where staining is the opposite. Importantly, expression of p130 is linked to cellular quiescence and is not found to accumulate in the nucleus of cells that are just transiting through G1. This confirms that the ascites derived spheroids are dormant. See Fig. 4A-E and described on page 9, lines 201-7.</p><disp-quote content-type="editor-comment"><p>(7) Overall, the findings are interesting in the context of cancer dissemination. There is not enough evidence for cancer dormancy and the importance of Netrin signaling in the survival of cancer dormancy. Overexpression of Netrin increases phosphorylation of ERK, leading one to expect an increase in proliferation. This suggests that Netrin breaks cancer cells out of dormancy, into a proliferative state.</p></disp-quote><p>We have found that the discovery of Netrin activation of MEK-ERK in growth arrested cells is counterintuitive to many cancer researchers. However, this axis exists in other paradigms of Netrin signaling in axon outgrowth that are not proliferation related (see citation 26, Forcet et al. Nature 417; 443-7 as an example). We have added Fig. 5D and descriptions on page 11, lines 244-52 to better clarify that Netrins CAN’T induce cell proliferation through ERK. Addition of recombinant Netrin-1 can only induce ERK phosphorylation in suspension culture conditions and not in quiescent adherent conditions. The small magnitude of ERK phosphorylation induced by Netrin-1 in suspension compared to treating adherent, quiescent cells with the same concentration of mitogenic EGF further emphasizes that this is not a proliferative signal. Lastly, the new xenograft experiment in Fig. 6A-D described on page 12, lines 266-81 demonstrates the growth arrested context in which Netrin signaling in dormant spheroids leads supports viability.</p><disp-quote content-type="editor-comment"><p>(8) If authors wish to claim cancer dormancy as the premise of their study, additional confirmatory experiments are required to support their claims. Alternatively, based on the current findings of the study, it would be best to change the premise of the article to Netrin signaling in cancer dissemination and survival of disseminated cancer spheroids rather than cancer dormancy.</p></disp-quote><p>I expect that this reviewer will agree that we have added more than sufficient explanations of background work on HGSOC spheroid dormancy from the literature, as well as new experiments that address their questions about dormancy in our experiments.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p><bold>Summary:</bold></p><p>In this article, the authors employed modified CRISPR screens [&quot;guide-only (GO)-CRISPR&quot;] in the attempt to identify the genes which may mediate cancer cell dormancy in the high grade serous ovarian cancer (HGSOC) spheroid culture models. Using this approach, they observed that abrogation of several of the components of the netrin (e.g., DCC, UNC5Hs) and MAPK pathways compromise the survival of non-proliferative ovarian cancer cells. This strategy was complemented by the RNAseq approach which revealed that a number of the components of the netrin pathway are upregulated in non-proliferative ovarian cancer cells and that their overexpression is lost upon disruption of DYRK1A kinase that has been previously demonstrated to play a major role in survival of these cells. Perampalam et al. then employed a battery of cell biology approaches to support the model whereby the Netrin signaling governs the MEK-ERK axis to support survival of non-proliferative ovarian cancer cells. Moreover, the authors show that overexpression of Netrins 1 and 3 bolsters dissemination of ovarian cancer cells in the xenograft mouse model, while also providing evidence that high levels of the aforementioned factors are associated with poor prognosis of HGSOC patients.</p><p>Strengths:</p><p>Overall it was thought that this study is of potentially broad interest in as much as it provides previously unappreciated insights into the potential molecular underpinnings of cancer cell dormancy, which has been associated with therapy resistance, disease dissemination, and relapse as well as poor prognosis. Notwithstanding the potential limitations of cellular models in mimicking cancer cell dormancy, it was thought that the authors provided sufficient support for their model that netrin signaling drives survival of non-proliferating ovarian cancer cells and their dissemination. Collectively, it was thought that these findings hold a promise to significantly contribute to the understanding of the molecular mechanisms of cancer cell dormancy and in the long term may provide a molecular basis to address this emerging major issue in the clinical practice.</p></disp-quote><p>Thanks for the kind words about the importance of our work in the broader challenges of cancer treatment.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>Several issues were observed regarding methodology and data interpretation. The major concerns were related to the reliability of modelling cancer cell dormancy. To this end, it was relatively hard to appreciate how the employed spheroid model allows to distinguish between dormant and e.g., quiescent or even senescent cells. This was in contrast to solid evidence that netrin signaling stimulates abdominal dissemination of ovarian cancer cells in the mouse xenograft and their survival in organoid culture. Moreover, the role of ERK in mediating the effects of netrin signaling in the context of the survival of non-proliferative ovarian cancer cells was found to be somewhat underdeveloped.</p></disp-quote><p>Experiments previously published in citation 7 show that growth arrest in patient ascites derived spheroids is fully reversible and that argued against non-proliferative spheroids being a form of senescence and moved this work into the dormancy field. We have added extensive new support for our model systems and data to address the counterintuitive aspects of MEK-ERK signaling in survival instead of proliferation.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 Recommendations for Authors</bold></p><p>(1) A better characterization of the spheroid model may be warranted, including staining for the markers of quiescence and senescence (including combining these markers with staining for the components of the netrin pathway)</p></disp-quote><p>See Figure 1A and page 6, lines 126-36 where we have added blots for Ki67 and p130 to better emphasize the arrested proliferative state of cells in our screening conditions. We have also added these same controls for patient ascites-derived spheroids in Figure 4 and described on page 9, lines 203-7. One realization from this CRISPR screen, and others in our lab, is that it identifies functionally important aspects of cell physiology and not necessarily ones that are easily explored using commercially available antibodies. Netrin-1 and -3 staining of patient derived spheroids in Fig. 4, as well as cell line spheroids stained in Fig. 4 Supplement 1 further support the relevance of this pathway in dormant cancer cells because Netrins are expressed in the right place at the right time. The Netrin-1 stimulation experiments in Fig. 5C were originally carried out to probe HGSOC cells for functionality of Netrin receptors since we couldn’t reliably detected them by blotting or staining with available antibodies. This demonstrates that this pathway is active in the various HGSOC cell lines we’ve used and specifically, using OVCAR8 cells, we show it is only active in suspension culture conditions.</p><disp-quote content-type="editor-comment"><p>(2) In figure 1A it appears that total p38 levels are reduced in some cell lines in spheroid vs. adherent culture. The authors should comment on this.</p></disp-quote><p>These blots have been updated to be more clear. Overall p38 levels may be reduced in some cell lines and when compared with activation levels of phosphorylated p38 it suggests the fraction of activated p38 is higher. OVCAR8 cells may be an exception where the overall activity level remains approximately the same.</p><disp-quote content-type="editor-comment"><p>(3) The authors should perhaps provide a clearer rationale for choosing to focus on the netrin signaling vs. e.g., GPCR signaling, and consider more explicit defining of &quot;primary&quot; vs. &quot;tertiary&quot; categories in Reactome gene set analysis.</p></disp-quote><p>We’ve updated Fig. 1E and the text on page7, lines 161-5 to illustrate which gene categories identified in the screen belong to which tiers of Reactome categories. It better visualizes why we have investigated the Axon guidance pathway that includes Netrin because it is a highly specific signaling pathway that scores similarly to the broader and less specific categories at the very top of the list. As an aside, the GPCR signaling and GPCR downstream signaling have proven to be fairly intractable categories. As best we can tell the GPCR downstream signaling category is full of MAPK family members and likely represents some redundancy with MAPK further down.</p><disp-quote content-type="editor-comment"><p>(4) In figure 3A-C, including factors whose expression did not appear to change between adherent and suspension conditions may be warranted as the internal control. Figure 3D-F may benefit from some sort of quantification.</p></disp-quote><p>The mRNA expression levels are normalized to GAPDH as an internal control. We have updated this figure and re-plotted it as fold change relative to adherent culture cells with statistical comparisons to indicate which are significantly upregulated in suspension culture.</p><p>The IHC experiments are now in Fig. 4D-F and show positive staining for Netrin-1 and -3. Netrin-3 is easiest to see, while Netrin-1 is trickier because the difference with the no primary antibody control isn’t intensity, but the tint of the DAB stain. We had to counter stain the patient spheroids with Hematoxylin in order for the slide scanner to find the best focal plane and make image registration between sections possible. This unfortunately makes the Netrin-1 staining rather subtle. For cell line spheroids in the Fig. 4, Supplement 1 we didn’t need the slide scanner and show negative controls without counter stain that are much more convincing of Netrin-1 detection and reassure us that our staining detects the intended target. We’ve updated the labels in Fig. 4 and Fig. 4, Supplement 1 for this to be more intuitive. Unfortunately, relying on the tint of the DAB stain leaves this as a qualitative experiment.</p><disp-quote content-type="editor-comment"><p>- In figure 4C-E the authors show that Netrin-1 stimulation induces ERK phosphorylation whereby it is argued that this is a &quot;low-level&quot; stimulation of ERK signaling required for the survival of ovarian cells in the suspension. This is however hard to appreciate, and it was thought that having adherent cells in parallel would be helpful to wage whether this indeed is a &quot;low level&quot; ERK activity. Moreover, the authors should likely include downstream substrates of ERK (e.g., RSKs) as well as p38 in these experiments. The control experiments for the effects of PD184352 on ERK phosphorylation also appear to be warranted. Finally, performing the experiments with PD184352 in the presence of Netrin-1 stimulation would also be advantageous.</p></disp-quote><p>We have added a new Netrin-1 stimulation experiment in Fig. 4D (described on page 11, line 244-52) that shows that Netrins can only activate very low levels of ERK phosphorylation in suspension when proliferation is arrested. Netrin-1 stimulation of quiescent adherent cells where stimulation of proliferation is possible shows that Netrins are unable to activate ERK phosphorylation in this condition. In contrast, we also stimulate quiescent adherent OVCAR8 cells with an equal concentration of EGF (a known mitogen) to offer high level ERK phosphorylation as a side by side comparison. I think that this offers clear evidence that Netrin signaling is inconsistent with inducing cell proliferation. We’ve also updated citations in the introduction to include citation 26 that offers a previously reported paradigm of Netrin-ERK signaling in axon outgrowth that is a non-cancer, non-proliferative context to remind readers that Netrins utilize MEK-ERK differently.</p><p>We highlight Netrin-MEK-ERK signaling as key to survival for a number of reasons. First, Netrin signaling in this paradigm does not fit the dependence receptor paradigm where loss of Netrin receptors protect against cell death. Fig. 5B rules this out as receptor loss never offers a survival advantage, but clearly receptor deletions compromise survival in suspension culture. Second, positive Netrin signaling is known to support survival by inactivating phosphorylation of DAPK1. We’ve added this experiment as Fig. 5 Supplement 1D and show that loss of Netrin receptors doesn’t reduce DAPK1 phosphorylation in a time course of suspension culture. Consequently, we conclude this isn’t the survival signal either. Since MEK and ERK family members scored in our screen, we investigated their role in survival. We now show two different MEK inhibitors with different inhibitory mechanisms to confirm that MEK inhibition induces cell death. In addition to the previous PD184352 inhibitor in our first submission, we’ve added Trametinib as well and this is shown in Fig. 5G. Since it is surprising the MEK inhibition can kill instead of just arrest proliferation, we’ve also added another cell death assay in which we show trypan blue dye exclusion as a second look at survival. This is now Fig. 5H. Lastly, we include Trametinib inhibition of ERK phosphorylation in these assays in Fig. 5I. While we leave open what takes place downstream of ERK, our model in Fig. 5J offers a very detailed look at the components upstream.</p><disp-quote content-type="editor-comment"><p>- Does inhibition of ERK prevent the abdominal spread of ovarian cancer cells? The authors may feel that this is out of the scope of the study, which I would agree with, but then the claims regarding ERK being the major mediator of the effects of netrin signaling should be perhaps slightly toned down.</p></disp-quote><p>We agree that loss of function xenograft experiments will enhance our discovery of Netrin’s role in dormancy and metastasis. We have added a new Fig. 6 that uses xenografts with Netrin receptor deficient OVCAR8 cells (UNC5 4KO). It demonstrates that two weeks following IP engraftment we can isolate spheroids from abdominal washes and that cells have entered a state of reduced proliferation as determined by lowered Ki67 expression as well as other proliferation inducing genes. In the case of UNC5 4KO cells, there is significant attrition of these cells as determined by recovering spheroids in adherent culture (Fig.6C) and by Alu PCR to detect human cells in abdominal washes (Fig. 6D). Lastly, xenografts of UNC5 4KO cells cause much less aggressive disease and significantly extend survival of these mice (Fig. 6E,F). Not exactly the experiment that the reviewer is asking for, but a clear indication that Netrin signaling supports survival in xenograft model of dormancy.</p><disp-quote content-type="editor-comment"><p>- Notwithstanding that this could be deduced from figures 6D and F, it would be helpful if the number of mice used in each experimental group is clearly annotated in the corresponding figure legends. Moreover, indicating the precise statistical tests that were used in the figures would be helpful (e.g., specifying whether anova is one-way, two-way, or?)</p></disp-quote><p>We have added labels to what is now Fig. 8B to indicate the number of animals used for each genotype of cells. We have also updated figure legends to include more details of statistical tests used in each instance.</p></body></sub-article></article>